ベーチェット病

出版社： 文光堂
著者：
発行日： 2016-03-01
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784830620379
電子書籍版： 2016-03-01 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,480 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,480 円(税込)

購入する

商品紹介

第一線の専門家による，本邦初の「ベーチェット病」に関する成書！本書では，この25年で多大に進歩を遂げた，ベーチェット病に関する，遺伝学，免疫学的な背景から，粘膜皮膚，眼，関節，消化管，神経，血管の各症状や病変と，その予後と治療までの重要なテーマについて，第一線の専門家がわかりやすく解説した．特に病理所見や皮膚や眼，消化管などの症状についてはカラー写真を豊富に盛り込んだ．ベーチェット病診療医待望の，本邦初の成書．

目次

  • ベーチェット病

    ―目次―

    1章? オーバービュー
    2章? ベーチェット病の遺伝学
    3章? 免疫学的異常
    4章? ベーチェット病と自然免疫
    5章? ベーチェット病の病理学的特徴
    6章? 粘膜皮膚病変
    7章? 眼症状
    8章? 関節病変
    9章? 消化管病変
    10章 神経ベーチェット病
    11章 血管病変
    12章 予後と治療

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 オーバービュー

P.4 掲載の参考文献
1) Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982 ; 100 : 1455-8.
PubMed
2) Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010 ; 42 : 698-702.
PubMed
3) Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-6.
PubMed
4) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease : a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
PubMed
5) Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992 : 140 : 410-9.
 
6) De Libero G. Sentinel function of broadly reactive human gamma delta T cells. Immunol Today 1997 ; 18 : 22-6.
PubMed
7) Hirohata S, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol 1998 ; 112 : 317-24.
PubMed
8) Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease : a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999 ; 42 : 1967-74.
PubMed
9) Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002 ; 31 : 205-10.
PubMed
10) Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000 ; 165 : 5814-21.
 
11) International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
 
12) Davatchi F, Shahram F, Akbarian M, Gharibdoost F, Nadji A, Chams C, et al. Accuracy of existing diagnosis criteria for Behcet's disease. In : Wechsler B, Godeau P, editors, Behcet's disease. Excerpta Medica, Amsterdam, 1993 : 225-8.
 
13) Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-62.
PubMed
14) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
PubMed
15) Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behcet's disease : maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009 ; 15 : 1769-71.
PubMed

2章 ベーチェット病の遺伝学

P.15 掲載の参考文献
1) Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999 ; 341 : 1284-91.
PubMed
2) Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis 2000 ; 59 : 622-5.
PubMed
3) Kone-Paut I, Geisler I, Wechsler B, Ozen S, Ozdogan H, Rozenbaum M, et al. Familial aggregation in Behcet's disease : high frequency in siblings and parents of pediatric probands. J Pediatr 1999 ; 135 : 89-93.
PubMed
4) Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behcet's disease, the Silk Road and HLA-B51 : historical and geographical perspectives. Tissue Antigens 1999 ; 54 : 213-20.
PubMed
5) Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982 ; 100 : 1455-8.
PubMed
6) Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K. HL-A5 and Behcet's disease. Lancet 1973 ; 2 : 1383-4.
PubMed
7) Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J. Whole-genome screening for susceptibility genes in multicase families with Behcet's disease. Arthritis Rheum 2005 ; 52 : 1836-42.
PubMed
8) Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010 ; 42 : 698-702.
PubMed
9) Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-6.
PubMed
10) Sano K, Yabuki K, Imagawa Y, Shiina T, Mizuki N, Ohno S, et al. The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease. Tissue Antigens 2001 ; 58 : 77-82.
PubMed
11) Takemoto Y, Naruse T, Namba K, Kitaichi N, Ota M, Shindo Y, et al. Re-evaluation of heterogeneity in HLA-B*510101 associated with Behcet's disease. Tissue Antigens 2008 ; 72 : 347-53.
PubMed
12) Gul A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ. Evidence for linkage of the HLA-B locus in Behcet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001 ; 44 : 239-40.
PubMed
13) de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease : a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009 ; 61 : 1287-96.
PubMed
14) Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, et al. Genetics of Behcet disease inside and outside the MHC. Ann Rheum Dis 2010 ; 69 : 747-54.
PubMed
15) Mizuki N, Ota M, Yabuki K, Katsuyama Y, Ando H, Palimeris GD, et al. Localization of the pathogenic gene of Behcet's disease by microsatellite analysis of three different populations. Invest Ophthalmol Vis Sci 2000 ; 41 : 3702-8.
PubMed
16) Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995 ; 38 : 426-33.
PubMed
17) Falk K, Rotzschke O, Takiguchi M, Gnau V, Stevanovic S, Jung G, et al. Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Beh cet's disease. Int Immunol 1995 ; 7 : 223-8.
 
18) Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet's disease. J Immunol 1993 ; 15 : 2273-82.
 
19) Ombrello MJ, Kirino Y, de Bakker PI, Gul A, Kastner DL, Remmers EF. Behcet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 2014 ; 111 : 8867-72.
PubMed
20) Vilches C, Parham P. KIR : diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002 ; 20 : 217-51.
PubMed
21) Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors : lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011 ; 132 : 315-25.
PubMed
22) O'Connor GM, McVicar D. The yin-yang of KIR3DL1/S1 : molecular mechanisms and cellular function. Crit Rev Immunol 2013 ; 33 : 203-18.
PubMed
23) Wildner G, Thurau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide : a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994 ; 24 : 2579-85.
 
24) Kurhan-Yavuz S, Direskeneli H, Bozkurt N, Ozyazgan Y, Bavbek T, Kazokoglu H, et al. Anti-MHC autoimmunity in Behcet's disease : T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol 2000 ; 120 : 162-6.
 
25) Takeuchi M, Usui Y, Okunuki Y, Zhang L, Ma J, Yamakawa N, et al. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. Invest Oph thalmol Vis Sci 2010 ; 51 : 3067-75.
 
26) Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study. Arthritis Res Ther 2009 ; 11 : R66.
PubMed
27) Hou S, Yang P, Du L, Zhou H, Lin X, Liu X, et al. SUMO4 gene polymorphisms in Chinese Han patients with Behcet's disease. Clin Immunol 2008 ; 129 : 170-5.
 
28) Hou S, Shu Q, Jiang Z, Chen Y, Li F, Chen F, et al. Replication study confirms the association between UBAC2 and Behcet's disease in two independent Chinese sets of patients and controls. Arthritis Res Ther 2012 ; 14 : R70.
 
29) Sawalha AH, Hughes T, Nadig A, Yilmaz V, Aksu K, Keser G, et al. A putative functional variant within the UBAC2 gene is associated with increased risk of Behcet's disease. Arthritis Rheum 2011 ; 63 : 3607-12.
PubMed
30) Kang EH, Kim JY, Takeuchi F, Kim JW, Shin K, Lee EY, et al. Associations between the HLA-A polymorphism and the clinical manifestations of Behcet's disease. Arthritis Res Ther 2011 ; 13 : R49.
PubMed
31) Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behcet's disease in Japanese patients. Clin Exp Rheumatol 2010 ; 28 (4 Suppl 60) : S39-44.
 
32) Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behcet's disease. Arthritis Rheum 2012 ; 64 : 2761-72.
PubMed
33) Wu Z, Zheng W, Xu J, Sun F, Chen H, Li P, et al. IL10 polymorphisms associated with Behcet's disease in Chinese Han. Hum Immunol 2014 ; 75 : 271-6.
 
34) Jiang Z, Yang P, Hou S, Du L, Xie L, Zhou H, et al. IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis 2010 ; 69 : 1325-8.
 
35) Hou S, Yang Z, Du L, Jiang Z, Shu Q, Chen Y, et al. Identification of a susceptibility locus in STAT4 for Behcet's disease in Han Chinese in a genome-wide association study. Arthritis Rheum 2012 ; 64 : 4104-13.
 
36) Xavier JM, Shahram F, Sousa I, Davatchi F, Matos M, Abdollahi BS, et al. FUT2 : filling the gap between genes and environment in Behcet's disease? Ann Rheum Dis 2015 ; 74 : 618-24.
PubMed
37) Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis 2013 ; 72 : 1510-6.
PubMed
38) Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev 2012 ; 11 : 687-98.
PubMed
39) Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha (1, 2) fucosyltransferase gene (FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem 1995 ; 270 : 4640-9.
PubMed
40) Serpa J, Mendes N, Reis CA, Santos Silva LF, Almeida R, Le Pendu J, et al. Two new FUT2 (fucosyltransferase 2 gene) missense polymorphisms, 739GaA and 839TaC, are partly responsible for non-secretor status in a Caucasian population from Northern Portugal. Biochem J 2004 ; 383 : 469-74.
 
41) McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. Hum Mol Genet 2010 ; 19 : 3468-76.
 
42) Smyth DJ, Cooper JD, Howson JM, Clarke P, Downes K, Mistry T, et al. FUT2 nonsecretor status links type 1 diabetes susceptibility and resistance to infection. Diabetes 2011 ; 60 : 3081-4.
PubMed
43) Haverkorn MJ, Goslings WR. Streptococci, ABO blood groups, and secretor status. Am J Hum Genet 1969 ; 21 : 360-75.
PubMed
44) Filen S, Lahesmaa R. GIMAP Proteins in T-Lymphocytes. J Signal Transduct 2010 ; 2010 : 268589
 
45) Ortiz-Fernandez L, Conde-Jaldon M, Garcia-Lozano JR, Montes-Cano MA, Ortego-Centeno N, Castillo-Palma MJ, et al. GIMAP and Behcet disease : no association in the European population. Ann Rheum Dis 2014 ; 73 : 1433-4.
PubMed
46) Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013 ; 45 : 202-7.
PubMed
47) Hou S, Xiao X, Li F, Jiang Z, Kijlstra A, Yang P. Two-stage association study in Chinese Han identifies two independent associations in CCR1/CCR3 locus as candidate for Behcet's disease susceptibility. Hum Genet 2012 ; 131 : 1841-50.
 
48) Palomino-Morales RJ, Rojas-Villarraga A, Gonzalez CI, Ramirez G, Anaya JM, Martin J. STAT4 but not TRAF1/C5 variants influence the risk of developing rheumatoid arthritis and systemic lupus erythematosus in Colombians. Genes Immun 2008 ; 9 : 379-82.
 
49) Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D : towards a new paradigm in immune recognition? Curr Opin Immunol 2002 ; 14 : 306-11.
PubMed
50) Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011 ; 43 : 761-7.
PubMed
51) Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Duzgun N, et al. Identification of multiple independent susceptibility loci in the HLA region in Behcet's disease. Nat Genet 2013 ; 45 : 319-24.
PubMed
52) Cassidy SA, Cheent KS, Khakoo SI. Effects of Peptide on NK cell-mediated MHC I recognition. Front Immunol 2014 ; 5 : 133.
PubMed
53) Sanjanwala B, Draghi M, Norman PJ, Guethlein LA, Parham P. Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1. J Immunol 2008 ; 181 : 6293-300.
PubMed
54) Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA) -E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998 ; 187 : 813-8.
 
55) Sayinalp N, Ozcebe OI, Ozdemir O, Haznedaroglu IC, Dundar S, Kirazli S. Cytokines in Behcet's disease. J Rheumatol 1996 ; 23 : 321-2.
PubMed
56) Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease ; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997 ; 24 : 128-32.
 
57) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
PubMed
58) Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, et al. Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol 1997 ; 107 : 241-7.
PubMed
59) Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease : analysis of published data on 369 patients. Semin Arthritis Rheum 2011 ; 41 : 61-70.
PubMed
60) Zhang M, Xu WD, Wen PF, Liang Y, Liu J, Pan HF, et al. Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease : an updated meta-analysis. Mol Vis 2013 ; 19 : 1913-24.
 
61) Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behcet's disease. Br J Dermatol 2006 ; 155 : 350-6.
 
62) Choy MK, Phipps ME. MICA polymorphism : biology and importance in immunity and disease. Trends Mol Med 2010 ; 16 : 97-106.
PubMed
63) Li P, Willie ST, Bauer S, Morris DL, Spies T, Strong RK. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 1999 ; 10 : 577-84.
 
64) Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999 ; 285 (5428) : 727-9.
 
65) Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8 alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001 ; 2 : 255-60.
 
66) Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001 ; 53 : 279-87.
PubMed
67) Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene : a strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci U S A 1997 ; 94 : 1298-303.
PubMed
68) Hughes EH, Collins RW, Kondeatis E, Wallace GR, Graham EM, Vaughan RW, et al. Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients. Tissue Antigens 2005 ; 66 : 195-9.
 
69) Ota M, Mizuki N, Katsuyama Y, Tamiya G, Shiina T, Oka A, et al. The critical region for Behcet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999 ; 64 : 1406-10.
PubMed
70) Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999 ; 42 : 1961-6.
 
71) Wallace GR, Verity DH, Delamaine LJ, Ohno S, Inoko H, Ota M, et al. MIC-A allele profiles and HLA class I associations in Behcet's disease. Immunogenetics 1999 ; 49 : 613-7.
 
72) Cohen R, Metzger S, Nahir M, Chajek-Shaul T. Association of the MIC-A gene and HLA-B51 with Behcet's disease in Arabs and non-Ashkenazi Jews in Israel. Ann Rheum Dis 2002 ; 61 : 157-60.
 

3章 免疫学的異常

P.30 掲載の参考文献
1) Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 ; 36 : 362-71.
PubMed
2) Hayasaki N, Ito M, Suzuki T, Ina K, Ando T, Kusugami K, et al. Neutrophilic phlebitis is characteristic of intestinal Behcet's disease and simple ulcer syndrome. Histopathology 2004 ; 45 : 377-83.
PubMed
3) Martinon F, Aksentijevich I. New players driving inflammation in monogenic autoinflammatory diseases. Nat Rev Rheumatol, 2015 ; 11 : 11-20.
PubMed
4) Hamzaoui K, Hamzaoui A, Hentati F, Kahan A, Ayed K, Chabbou A, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 ; 21 : 2301-6.
PubMed
5) Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W. The histopathology of pathergy : a chronologic study of skin hyperreactivity in Behcet's disease. Int J Dermatol 1998 ; 37 : 929-33.
PubMed
6) Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995 ; 132 : 901-7.
 
7) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease-a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
PubMed
8) Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992 ; 140 : 410-9.
 
9) Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol 2004 ; 22 : S59-63.
PubMed
10) Hirohata S, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol 1998 ; 112 : 317-24.
PubMed
11) Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol 1982 ; 100 : 1455-8.
PubMed
12) de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease : a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009 ; 61 : 1287-96.
PubMed
13) Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010 ; 42 : 698-702.
PubMed
14) Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-6.
PubMed
15) Kang EH, Kim JY, Takeuchi F, Kim JW, Shin K, Lee EY, et al. Associations between the HLA-A polymorphism and the clinical manifestation of Behcet's disease. Arthritis Res Ther 2011 ; 13 : R49.
PubMed
16) Chung YM, Yeh TS, Sheu MM, Chen MS, Wen MS, Tsai HY, et al. Behcet's disease with ocular involvement in Taiwan : a joint survey of six major ophthalmological departments. J Formos Med Assoc 1990 ; 89 : 413-7.
PubMed
17) Mizuki N, Ohno S, Ando H, Chen L, Palimeris GD, Stavropoulos-Ghiokas E, et al. A strong association between HLA-B*5101 and Behcet's disease in Greek patients. Tissue Antigens 1997 ; 50 : 57-60.
 
18) Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, et al. Genetics of Behcet's disease inside and outside the MHC. Ann Rheum Dis 2010 ; 69 : 747-54.
PubMed
19) Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene : a strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci USA 1997 ; 94 : 1298-303.
PubMed
20) Mizuki N, Ota M, Katsuyama Y, Yabuki K, Ando H, Goto K, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999 ; 42 : 1961-6.
 
21) Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci USA 2013 ; 110 : 8134-9.
PubMed
22) Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol 2014 ; 9 : 181-218.
PubMed
23) Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, et al. Neutrophil CD64 expression in Behcet's disease. J Rheumatol 2005 ; 32 : 849-52.
PubMed
24) Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis 1996 ; 55 : 128-33.
PubMed
25) Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 : S19-24.
 
26) Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995 ; 38 : 426-33.
PubMed
27) Matsumara N, Mizushima Y. Leukocyte movement and colchicine treatment in Behcet's disease. Lancet 1975 ; 2 : 813.
 
28) Neves FS, Carrasco S, Goldenstein-Schainberg C, Goncalves CR, de Mello SB. Neutrophil hyperchemotaxis in Behcet's disease : a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 2009 ; 28 : 1403-10.
PubMed
29) Acikgoz N, Ermis N, Yagmur J, Cansel M, Karincaoglu Y, Atas H, et al. Elevated oxidative stress markers and its relationship with endothelial dysfunction in Behcet disease. Angiology 2011 ; 62 : 296-300.
PubMed
30) Najim RA, Sharquie KE, Abu-Raghif AR. Oxidative stress in patients with Behcet's disease : I correlation with severity and clinical parameters. J Dermatol 2007 ; 34 : 308-14.
PubMed
31) Romagnani S. Human Th17 cells. Arthritis Res Ther 2008 ; 10 : 206.
PubMed
32) Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998 ; 161 : 5821-4.
PubMed
33) Kimura MY, Nakayama T. Differentiation of NK1 and NK2 cells. Crit Rev Immunol 2005 ; 25 : 361-74.
PubMed
34) Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, et al. Natural killer cells control a T-helper 1 response in patients with Behcet's disease. Arthritis Res Ther 2010 ; 12 : R80.
 
35) Onder M, Bozkurt M, Gurer MA, Gulekon A, Sezgin P, Imir T. Natural cellular cytotoxicity in Behcet's disease. J Dermatol 1994 ; 21 : 239-43.
PubMed
36) Kaneko F, Takahashi Y, Muramatsu R, Adachi K, Miura Y, Nakane A, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behcet's disease. Br J Dermatol 1985 ; 113 : 313-8.
PubMed
37) Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol 1988 ; 71 : 126-31.
PubMed
38) Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Oligoclonal T cell expansions in patients with Behcet's disease. Clin Exp Immunol 1999 ; 117 : 166-70.
PubMed
39) Esin S, Gul A, Hodara V, Jeddi-Tehrani M, Dilsen N, Konice M, et al. Peripheral blood T cell expansions in patients with Behcet's disease. Clin Exp Immunol 1997 ; 107 : 520-7.
 
40) Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006 ; 12 : 271-7.
PubMed
41) Clemente A, Cambra A, Munoz-Saa I, Crespi C, Pallares L, Juan A, et al. Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Behcet's disease patients and healthy controls. Immunol Lett 2010 ; 129 : 57-63.
 
42) Yasuoka H, Yamaguchi Y, Mizuki N, Nishida T, Kawakami Y, Kuwana M. Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Behcet's disease and HLA-B51. Clin Exp Rheumatol 2008 ; 26 : S59-63.
PubMed
43) Ling E, Shubinsky G, Press J. Increased proportion of CD3+ CD4- CD8-double-negative T cells in peripheral blood of children with Behcet's disease. Autoimmun Rev 2007 ; 6 : 237-40.
PubMed
44) Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Behcet's disease : role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 2003 ; 141 : 33-40.
PubMed
45) Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, et al. Vgamma9/Vdelta2 T lymphocytes in Italian patients with Behcet's disease : evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Res Ther 2003 ; 5 : R262-8.
PubMed
46) Accardo-Palumbo A, Giardina AR, Ciccia F, Ferrante A, Principato A, Impastato R, et al. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behcet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 2010 ; 12 : R109.
PubMed
47) Yato H, Matsumoto Y. CD56+ T cells in the peripheral blood of uveitis patients. Br J Ophthalmol 1999 ; 83 : 1386-8.
PubMed
48) Hamzaoui K, Kamoun M, Houman H, Hentati F, Hamza M, Ayed K, et al. Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behcet's disease. J Neuroimmunol 2006 ; 175 : 160-8.
PubMed
49) Yu HG, Lee DS, Seo JM, Ahn JK, Yu YS, Lee WJ, et al. The number of CD8+T cells and NKT cells increases in the aqueous humor of patients with Behcet's uveitis. Clin Exp Immunol 2004 ; 137 : 437-43.
PubMed
50) Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. CD-8 bright CD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 2005 ; 175 : 6133-42.
 
51) Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 2004 ; 50 : 2291-5.
PubMed
52) Houman H, Hamzaoui A, Ben Ghorbal I, Khanfir M, Feki M, Hamzaoui K. Abnormal expression of chemokine receptors in Behcet's disease : relationship to Intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 2004 ; 23 : 267-73.
PubMed
53) Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, andchemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is alsoobserved in patients with BD. Scand J Rheumatol 2006 ; 35 : 472-5.
 
54) Ferrante A, Ciccia F, Principato A, Giardina AR, Impastato R, Peralta S, et al. A Th1 but not a Th17 response is present in the gastrointestinal involvement of Behcet's disease. Clin Exp Rheumatol 2010 ; 28 : S27-30.
 
55) Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behcet's disease : a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999 ; 42 : 1967-74.
PubMed
56) Hirohata S, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behcet's disease (BD). Clin Exp Immunol 1998 ; 112 : 317-24.
PubMed
57) Direskeneli H, Fujita H, Akdis CA. Regulation of TH17 and regulatory T cells in patients with Behcet disease. J Allergy Clin Immunol 2011 ; 128 : 665-6.
PubMed
58) Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008 ; 49 : 3058-64.
 
59) Chi W, Zhou S, Yang P, Chen L. CD4+T cells from Behcet patients produce high levels of IL-17. Eye Sci 2011 ; 26 : 65-9.
 
60) Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th-17 and RORyt mRNA in Behcet's Disease. Med Sci Monit 2011 ; 17 : CR227-34.
 
61) Kim J, Park JA, Lee EY, Lee YJ, Song YW, Lee EB. Imbalance of Th17 to Th1 cells in Behcet's disease. Clin Exp Rheumatol 2010 ; 28 : S16-9.
 
62) Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H. RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behcet's disease. J Neuroimmunol 2011 ; 233 : 249-53.
PubMed
63) Geri G, Terrier B, Rosenzwajg M, Wechsler B, in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 2011 ; 128 : 655-64.
PubMed
64) Buckner JH. Mechanisms of impaired regulation by CD4 (+) CD25 (+) FOXP3 (+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010 ; 10 : 849-59.
PubMed
65) Pekiner FN, Aytugar E, Demirel GY, Borahan MO. Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behcet's disease and recurrent aphthous ulcerations. J Oral Pathol Med 2012 ; 41 : 73-9.
 
66) Hamzaoui K. Paradoxical high regulatory T cell activity in Behcet's disease. Clin Exp Rheumatol 2007 ; 25 : S107-13.
PubMed
67) Hamzaoui K, Hamzaoui A, Houman H. CD4+ CD25+ regulatory T cells in patients with Behcet's disease. Clin Exp Rheumatol 2006 ; 24 : S71-8.
PubMed
68) Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack : a possible predictive marker of ocular attack. Mod Rheumatol 2008 ; 18 : 354-8.
PubMed
69) Cervera R, Navarro M, Lopez-Soto A, Cid MC, Font J, Esparza J, et al. Antibodies to endothelial cells in Behcet's disease : cell-binding heterogeneity and association with clinical activity. Ann Rheum Dis 1994 ; 53 : 265-7.
PubMed
70) Aydintug AO, Tokgoz G, D'Cruz DP, Gurler A, Cervera R, Duzgun N, et al. Antibodies to endothelial cells in patients with Behcet's disease. Clin Immunol Immunopathol 1993 ; 67 : 157-62.
PubMed
71) Direskeneli H, Keser G, D'Cruz D, Khamashta MA, Akoglu T, Yazici H, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behcet's disease. Clin Rheumatol 1995 ; 14 : 55-61.
PubMed
72) Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease. Arthritis Rheum 2003 ; 48 : 2025-35.
PubMed
73) Lee JH, Cho SB, Bang D, Oh SH, Ahn KJ, Kim J, et al. Human anti-alpha-enolase antibody in sera from patients with Behcet's disease and rheumatologic disorders. Clin Exp Rheumatol 2009 ; 27 : S63-6.
PubMed
74) Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behcet's disease : a reassessment. Rheumatology (Oxford) 2001 ; 40 : 192-5.
PubMed
75) Briani C, Doria A, Marcolongo R, Tognon S, Ruggero S, Toffanin E, et al. Increased titres of IgM anti-heparan sulfate antibody in Behcet's disease. Clin Exp Rheumatol 2006 ; 24 : S104-7.
PubMed
76) Lu Y, Ye P, Chen SL, Tan EM, Chan EK. Identification of kinectin as a novel Behcet's disease autoantigen. Arthritis Res Ther 2005 ; 7 : R1133-9.
PubMed
77) Direskeneli GS, Celet B, Eksioglu-Demiralp E, Direskeneli H. Human HSP 60 peptide responsive T cell lines are similarly present in both Behcet's disease patients and healthy controls. Immunol Lett 2001 ; 79 : 203-8.
 
78) de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behcet's disease patients and controls. Invest Ophthalmol Vis Sci 2000 ; 41 : 3480-4.
 
79) Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infect Immun 1991 ; 59 : 1434-41.
PubMed
80) Yasuoka H, Okazaki Y, Kawakami Y, Hirakata M, Inoko H, Ikeda Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behcet's disease. Arthritis Rheum 2004 ; 50 : 3658-62.
 

4章 ベーチェット病と自然免疫

P.45 掲載の参考文献
1) McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006 ; 3 : e297.
PubMed
2) Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, et al. Clinical guidelines and definitions of autoinflammatory diseases : contrasts and comparisons with autoimmunity-a comprehensive review. Clin Rev Allergy Immunol 2013 ; 45 : 227-35.
PubMed
3) Consortium TFF. A candidate gene for familial Mediterranean fever. Nat Genet 1997 ; 17 : 25-31.
 
4) Stehlik C, Reed JC. The PYRIN connection : novel players in innate immunity and inflammation. J Exp Med 2004 ; 200 : 551-8.
PubMed
5) Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001 ; 27 : 20-1.
PubMed
6) Denman AM, Fialkow PJ, Pelton BK, Salo AC, Appleford DJ, Gilchrist C. Lymphocyte abnormalities in Behcet's syndrome. Clin Exp Immunol 1980 ; 42 : 175-85.
PubMed
7) Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E. Relationship between periodontal findings and Behcet's disease : a controlled study. J Clin Periodontol 2007 ; 34 : 485-91.
PubMed
8) Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet's disease and is associated with disease severity. Rheumatology (Oxford) 2004 ; 43 : 1028-33.
PubMed
9) Celenligil-Nazliel H, Kansu E, Ebersole JL. Periodontal findings and systemic antibody responses to oral microorganisms in Behcet's disease. J Periodontol 1999 ; 70 : 1449-56.
PubMed
10) Umit K, Gonca M, Ismail S, Salih P, Osman K, Hakan E, et al. The close association between dental and periodontal treatments and oral ulcer course in Behcet's disease : a prospective clinical study. J Oral Pathol Med 2009 ; 38 : 410-5.
 
11) Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J 1997 ; 38 : 444-54.
PubMed
12) Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, et al. Chemiluminescence of neutrophils from patients with Behcet's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990 ; 35 : 43-8.
PubMed
13) Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celic I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum 1996 ; 39 : 2062-5.
 
14) Isogai E, Isogai H, Yokota K, Oguma K, Kimura K, Kubota T, et al. Experimental model for Behcet's disease in gnotobiotic mice infected with Streptococcus sanguis. In : Behcet's desease. Bang E, Lee ES, Lee S, eds. Design Mecca Publishing Co., Korea. 2001 : 133-8.
 
15) Niwa Y, Mizushima Y. Neutrophil-potentiating factors released from stimulated lymphocytes ; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behcet's disease. Clin Exp Immunol 1990 ; 79 : 353-60.
 
16) Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992 ; 140 : 410-9.
 
17) The Behcet's Disease Research Committee of Japan. Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet's disease : a multicenter study. J Rheumatol 1989 ; 16 : 506-11.
PubMed
18) Hamzaoui K, Ayed K, Slim A, Hamza M, Touraine J. Natural killer cell activity, interferon-gamma and antibodies to herpes viruses in patients with Behcet's disease. Clin Exp Immunol 1990 ; 79 : 28-34.
PubMed
19) Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet's syndrome and recurrent oral ulcers. Lancet 1982 ; 2 : 1356-61.
PubMed
20) Sohn S, Lee ES, Bang D, Lee S. Behcet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998 ; 8 : 21-3.
 
21) Shim J, Byun HO, Lee YD, Lee ES, Sohn S. Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behcet's disease-like mouse model. Gene Ther 2009 ; 16 : 415-25.
PubMed
22) Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome : a randomized double-blind trial. Br J Rheumatol 1988 ; 27 : 300-2.
 
23) Yokota K, Hayashi S, Araki Y, Isogai E, Kotake S, Yoshikawa K. Characterization of Streptococcus sanguis isolated from patients with Behcet's disease. Microbiol Immunol 1995 ; 39 : 729-32.
PubMed
24) Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev 2015 ; 14 : 269-76.
PubMed
25) Hatemi G, Yazici H. Behcet's syndrome and micro-organisms. Best Pract Res Clin Rheumatol 2011 ; 25 : 389-406.
PubMed
26) Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W. The histopathology of pathergy : a chronologic study of skin hyperreactivity in Behcet's disease. Int J Dermatol 1998 ; 37 : 929-33.
PubMed
27) Kobayashi M, Ito M, Nakagawa A, Matsushita M, NIshikimi N, Sakurai T, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 ; 36 : 362-71.
PubMed
28) Hayasaki N, Ito M, Suzuki T, Ina K, Ando T, Kusugami K, et al. Neutrophilic phlebitis is characteristic of intestinal Behcet's disease and simple ulcer syndrome. Histopathology 2004 ; 45 : 377-83.
PubMed
29) Hamzaoui K, Hamzaoui A, Hentati F, Kahan A, Ayed K, Chabbou A, et al. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behcet's disease. J Rheumatol 1994 ; 21 : 2301-6.
PubMed
30) Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of γδ T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006 ; 12 : 271-7.
 
31) Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behcet's disease. Lancet 1975 ; 2 : 813.
PubMed
32) Sobel JD, Haim S, Obedeanu N, Meshulam T, Merzbach D. Polymorphonuclear leucocyte function in Behcet's disease. J Clin Pathol 1977 ; 30 : 250-3.
PubMed
33) Neves FS, Spiller F. Possible mechanisms of neutrophil activation in Behcet's disease. Int Immunopharmacol 2013 ; 17 : 1206-10.
PubMed
34) Efthimiou J, Addison IE, Johnson BV. In vivo leucocyte migration in Behcet's syndrome. Ann Rheum Dis 1989 ; 48 : 206-10.
PubMed
35) Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, et al. Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet's disease. J Rheumatol 1997 ; 24 : 1332-6.
PubMed
36) Fujimori K, Oh-i K, Takeuchi M, Yamakawa N, Hattori T, Kezuka T, et al. Circulating neutrophils in Behcet disease is resistant for apoptotic cell death in the remission phase of uveitis. Graefes Arch Clin Exp Ophthalmol 2008 ; 246 : 285-90.
PubMed
37) Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (5 Suppl. 24) : S19-24.
 
38) Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, et al. Neutrophil CD64 expression in Behcet's disease. J Rheumatol 2005 ; 32 : 849-52.
PubMed
39) Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, et al. Excessive function of peripheral blood neutrophils from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995 ; 38 : 426-33.
PubMed
40) Neves FS, Carrasco S, Goldenstein-Schainberg C, Goncalves CR, de Mello SB. Neutrophil hyperchemotaxis in Behcet's disease : a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 2009 ; 28 : 1403-10.
PubMed
41) Sahin S, Akoglu T, Direskeneli H, Sen LS, Lawrence R. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcet's disease. Ann Rheum Dis 1996 ; 55 : 128-33.
PubMed
42) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
PubMed
43) Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease : high levels may indicate vascular involvement. Int J Dermatol 2009 ; 48 : 259-64.
PubMed
44) Ture-Ozdemir F, Tulunay A, Elbasi MO, Tatli I, Maurer AM, Mumcu G, et al. Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet's disease. Rheumatology (Oxford) 2013 ; 52 : 800-5.
PubMed
45) Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behcet's disease. J Rheumatol 1990 ; 17 : 1428-9.
PubMed
46) Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet's disease. Does interleukin-1beta play a major role in Behcet's synovitis? Rheumatol Int 2006 ; 26 : 608-13.
 
47) Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet's disease. Autoimmun Rev 2015 ; 14 : 1-9.
PubMed
48) Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007 ; 6 : 169-75.
PubMed
49) Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T (H) 17 cells. Nature 2008 ; 454 : 350-2.
 
50) Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010 ; 42 : 703-6.
PubMed
51) Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010 ; 42 : 698-702.
PubMed
52) Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 2011 ; 128 : 655-64.
PubMed
53) Ekinci NS, Alpsoy E, Karakas AA, Yilmaz SB, Yegin O. IL-17A has an important role in the acute attacks of Behcet's disease. J Invest Dermatol 2010 ; 130 : 2136-8.
PubMed
54) Aktas Cetin E, Cosan F, Cefle A, Deniz G. IL-22-secreting Th22 and IFN-γ-secreting Th17 cells in Behcet's disease. Mod Rheumatol 2014 ; 24 : 802-7.
 
55) Shimizu J, Takai K, Fujiwara N, Arimitsu N, Ueda Y, Wakisaka S, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behcet's disease. Clin Exp Immunol 2012 ; 168 : 68-74.
 
56) Na SY, Park MJ, Park S, Lee ES. Up-regulation of Th17 and related cytokines in Behcet's disease corresponding to disease activity. Clin Exp Rheumatol 2013 ; 31 : 32-40.
 
57) Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002 ; 31 : 205-10.
PubMed
58) Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A. Expression of Th-17 and RORγt mRNA in Behcet's Disease. Med Sci Monit 2011 ; 17 : CR227-34.
 
59) Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014 ; 13 : 668-77.
PubMed
60) Fortune F, Walker J, Lehner T. The expression of γδ T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behcet's syndrome. Clin Exp Immunol 1990 ; 82 : 326-32.
 
61) Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Behcet's disease : role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 2003 ; 141 : 33-40.
PubMed
62) Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999 ; 118 : 451-7.
PubMed
63) Parlakgul G, Guney E, Erer B, Kihcaslan Z, Direskeneli H, Gul A, et al. Expression of regulatory receptors on γδ T cells and their cytokine production in Behcet's disease. Arthritis Res Ther 2013 ; 15 : R15.
 
64) Kaneko F, Takahashi Y, Muramatsu R, Adachi K, Miura Y, Nakane A, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behcet's disease. Br J Dermatol 1985 ; 113 : 313-8.
PubMed
65) Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol 1988 ; 71 : 126-31.
PubMed
66) Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol 2004 ; 22 : S59-63.
PubMed
67) Hamzaoui K, Berraies A, Kaabachi W, Ammar J, Hamzaoui A. Pulmonary manifestations in Behcet disease : impaired natural killer cells activity. Multidiscip Respir Med 2013 ; 8 : 29.
PubMed
68) Yamaguchi Y, Takahashi H, Satoh T, Okazaki Y, Mizuki N, Takahashi K, et al. Natural killer cells control a T-helper 1 response in patients with Behcet's disease. Arthritis Res Ther 2010 ; 12 : R80.
 
69) Muller W, Lehner T. Quantitative electron microscopy microscopical analysis of leukocyte infiltration in oral ulcers of Behcet's syndrome. Br J Dermatol 1982 ; 106 : 535-44.
PubMed
70) Poulter LW, Lehner T. Immunohistology of oral lesions from patients with recurrent oral ulcers and Behcet's syndrome. Clin Exp Immunol 1989 ; 78 : 189-95.
PubMed
71) Cho S, Kim J, Cho SB, Zheng Z, Choi MJ, Kim DY, et al. Immunopathogenic characterization of cutaneous inflammation in Behcet's disease. J Eur Acad Dermatol Venereol 2014 ; 28 : 51-7.
 
72) Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoglu T. Monocyte activity in Behcet's disease. Br J Rheumatol 1996 ; 35 : 424-9.
PubMed
73) Shim JA, Cho S, Bang D, Anower AKMM, Kim DY, Cho S, et al. Differential expression of monocyte/macrophage markers between active and inactive stage of patients with Behcet's disease. Pathol Discov 2013 ; 1 : 2.
 
74) Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis ChC. Serum of patients with Behcet's disease induces classica (l pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003 ; 206 : 225-32.
 
75) Castrichini M, Lazzerini PE, Gamberucci A, Capecchi PL, Franceschini R, Natale M, et al. The purinergic P2×7 receptor is expressed on monocytes in Behcet's disease and is modulated by TNF-α. Eur J Immunol 2014 ; 44 : 227-38.
 
76) Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003 ; 21 : 335-76.
PubMed
77) Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008 ; 8 : 279-89.
PubMed
78) Kono H, Onda A, Yanagida T. Molecular determinants of sterile inflammation. Curr Opin Immunol 2014 ; 26 : 147-56.
PubMed
79) Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford) 2008 ; 47 : 840-8.
 
80) Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, et al. Association of reduced heme oxygenase-1 with excessive Tolllike receptor 4 expression in peripheral blood mononuclear cells in Behcet's disease. Arthritis Res Ther 2008 ; 10 : R16.
PubMed
81) Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013 ; 54 : 402-14.
 
82) Nara K, Kurokawa MS, Chiba S, Yoshikawa H, Tsukikawa S, Matsuda T, et al. Involvement of innate immunity in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2008 ; 152 : 245-51.
PubMed
83) Yavuz S, Elbir Y, Tulunay A, Eksioglu-Demiralp E, Direskeneli H. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol Int 2008 ; 28 : 401-6.
PubMed
84) Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A 2013 ; 110 : 8134-9.
PubMed
85) Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O. Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease. Clin Exp Dermatol 2006 ; 31 : 699-701.
PubMed
86) Sada T, Ota M, Katsuyama Y, Meguro A, Nomura E, Uemoto R, et al. Association analysis of Toll-like receptor 7 gene polymorphisms and Behcet's disease in Japanese patients. Hum Immunol 2011 ; 72 : 269-72.
PubMed
87) Turner MW. Mannose-binding lectin : the pluripotent molecule of the innate immune system. Immunol Today 1996 ; 17 : 532-40.
PubMed
88) Matsushita M, Endo Y, Fujita T. Structural and functional overview of the lectin complement pathway : its molecular basis and physiological implication. Arch Immunol Ther Exp 2013 ; 61 : 273-83.
PubMed
89) Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005 ; 32 : 287-291.
PubMed
90) Mumcu G, Inanc N, Aydin SZ, Ergun T. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S32-6.
 
91) Kim J, Im CH, Kang EH, Lee EY, Lee YJ, Park KS. Mannose-binding lectin gene-2 polymorphisms and serum mannose-binding lectin levels in Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (Suppl. 53) : S13-7.
 
92) Caruso R, Warner N, Inohara N, Nunez G. NOD1 and NOD2 : Signaling, Host Defense, and Inflammatory Disease. Immunity 2014 ; 41 : 898-908.
PubMed
93) Hamzaoui K, Abid H, Berraies A, Ammar J, Hamzaoui A. NOD2 is highly expressed in Behcet disease with pulmonary manifestations. J Inflamm (Lond) 2012 ; 9 : 3.
PubMed
94) Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behcet's disease : correlations with disease activity and severity. Isr J Med Sci 1995 ; 31 : 345-8.
PubMed
95) Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet's disease. Does interleukin-1beta play a major role in Behcet's synovitis? Rheumatol Int 2006 ; 26 : 608-13.
 
96) Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behcet disease responsive to anakinra. Ann Intern Med 2008 ; 149 : 284-6.
PubMed
97) Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 2010 ; 29 : 209-10.
 
98) Centola M, Aksentijevich I, Kastner DL. The hereditary periodic fever syndromes : molecular analysis of a new family of inflammatory diseases. Hum Mol Genet 1998 ; 7 : 1581-8.
PubMed
99) Mansfield E, Chae JJ, Komarow HD, Brotz TM, Frucht DM, Aksentijevich I, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001 ; 98 : 851-9.
PubMed
100) Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013 ; 14 : 454-60.
PubMed
101) Shohat M, Halpern GJ. Familial Mediterranean fever-a review. Genet Med 2011 ; 13 : 487-98.
PubMed
102) Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS, et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995 ; 267 : 2000-3.
PubMed
103) Kono H, Orlowski GM, Patel Z, Rock KL. The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C. J Immunol 2012 ; 189 : 3734-40.
 
104) Martinon F, Mayor A, Tschopp J. The inflammasomes : guardians of the body. Annu Rev Immunol 2009 ; 27 : 229-65.
PubMed
105) Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009 ; 106 : 9021-6.
PubMed
106) Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007 ; 14 : 1457-66.
PubMed
107) Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity 2011 ; 34 : 755-68.
 
108) Hasegawa M, Imamura R, Kinoshita T, Matsumo to N, Masumoto J, Inohara N, et al. ASC-mediated NF-kappaB activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP. J Biol Chem. 2005 ; 280 : 15122-30.
 
109) Sugiyama R, Agematsu K, Migita K, Nakayama J, Mokuda S, Ogura F, et al. Defect of suppression of inflammasome-independent interleukin-8 secretion from SW982 synovial sarcoma cells by familial Mediterranean fever-derived pyrin mutations. Mol Biol Rep 2014 ; 41 : 545-53.
PubMed
110) Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A, et al. Phenotype-genotype correlation in familial Mediterranean fever : evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 1999 ; 7 : 287-92.
PubMed
111) Imirzalioglu N, Dursun A, Tastan B, Soysal Y, Yakicier MC. MEFV gene is a probable susceptibility gene for Behcet's disease. Scand J Rheumatol 2005 ; 34 : 56-8.
PubMed
112) Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Livneh A. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007 ; 36 : 48-52.
PubMed
113) Tasliyurt T, Yigit S, Rustemoglu A, Gul U, Ates O. Common MEFV gene mutations in Turkish patients with Behcet's disease. Gene 2013 ; 530 : 100-3.
PubMed
114) Atagunduz P, Ergun T, Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin Exp Rheumatol 2003 ; 21 (4 suppl. 30) : S35-7.
 
115) Yuksel S, Eren E, Hatemi G, Sahillioglu AC, Gultekin Y, Demiroz D, et al. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behcet's syndrome patients. Int Immunol 2014 ; 26 : 71-81.
PubMed
116) Nuki G. Colchicine : its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008 ; 10 : 218-27.
PubMed
117) Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 ; 440 : 237-41.
PubMed
118) Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980 ; 65 : 399-402.
PubMed
119) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-92.
 
120) Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, et al. Colchicine versus placebo in Behcet's disease : randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009 ; 19 : 542-9.
 
121) Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet's disease : a case series. Clin Rheumatol 2015 ; 34 : 1293-301.
PubMed
122) Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. Ann Rheum Dis 2012 ; 71 : 1589-91.
 
123) Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R. Successful use of canakinumab in a patient with resistant Behcet's disease. Clin Exp Rheumatol 2012 ; 30 : S115.
 
124) Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet's disease : a case series. Dermatology 2014 ; 228 : 211-4.
PubMed
125) Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease : an open-label pilot study. Ann Rheum Dis 2012 ; 71 : 563-6.
 

5章 ベーチェット病の病理学的特徴

P.63 掲載の参考文献
1) Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rheumatol 2001 ; 19 (suppl. 24) : S48-50.
 
2) Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, et al. Vascular involvement in Behcet's disease : relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002 ; 112 : 37-43.
PubMed
3) Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selection expression by sera from patients with active Behcet's disease : moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999 ; 91 : 330-7.
PubMed
4) Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002 ; 31 : 205-10.
PubMed
5) Mantas C, Direskeneli H, Oz D, Yavuz S, Akoglu T. IL-8 producing cells in patients with Behcet's disease. Clin Exp Rheumatol 2000 ; 18 : 249-51.
PubMed
6) Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, et al. Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan. Clin Exp Immunol 1997 ; 108 : 204-12.
PubMed
7) Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000 ; 165 : 5814-21.
 
8) Yamashita N, Kaneoka H, Kaneko S, Takeno M, Oneda K, Koizumi H, et al. Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol 1997 ; 107 : 241-7.
PubMed
9) Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012 ; 14 : R99.
PubMed
10) Matsui T, Kurokawa M, Kobata T, Oki S, Azuma M, Tohma S, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999 ; 162 : 4328-35.
 
11) Schroeder HE, Muller-Glauser W, Sallay K. Pathomorphologic features of the ulcerative stage of oral aphthous ulcerations. Oral Surg Oral Med Oral Pathol 1984 ; 58 : 293-305.
PubMed
12) Honma T, Saito T, Fujioka Y. Possible role of apoptotic cells of the oral epithelium in the pathogenesis of aphthous ulceration. Oral Surg Oral Med Oral Pathol 1985 ; 59 : 379-87.
PubMed
13) Ergun T, Gurbuz O, Harvell J, Jorizzo J, White W. The histopathology of pathergy : a chronologic study of skin hyperreactivity in Behcet's disease. Int J Dermatol 1998 ; 37 : 929-33.
PubMed
14) Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behcet's disease. Br J Dermatol 1995 ; 132 : 901-7.
 
15) Togashi A, Saito S, Kaneko F, Nakamura K, Oyama N. Skin prick test with self-saliva in patients with oral aphthoses : a diagnostic pathergy for Behcet's disease and recurrent aphthosis. Inflamm Allergy Drug Targets 2011 ; 10 : 164-70.
PubMed
16) Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet's disease in Japan : ophthalmologic aspects. Trans Am Ophthalmol Soc 1979 ; 77 : 225-79.
 
17) Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res Ther 2009 ; 11 : R17.
 
18) Hirohata S. Histopathology of central nervous system lesions in Behcet's disease. J Neurol Sci 2008 ; 267 : 41-7.
PubMed
19) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-13.
PubMed
20) Saadoun D, Asli B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Behcet disease : a series of 101 patients. Medicine (Baltimore) 2012 ; 91 : 18-24.
PubMed
21) Hirohata S, Kikuchi H. Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behcet's disease. Clin Exp Rheumatol 2009 ; 27 (2 Suppl 53) : S91-5.
 
22) Hamuryudan V, Oz B, Tuzun H, Yazici H. The menacing pulmonary artery aneurysms of Behcet's syndrome. Clin Exp Rheumatol 2004 ; 22 (4 Suppl 34) : S1-3.
 
23) Koklu S, Yuksel O, Onur I, Unverdi S, Biyikoglu I, Akbal E, et al. Ileocolonic involvement in Behcet's disease : endoscopic and histological evaluation. Digestion 2010 ; 81 : 214-7.
PubMed
24) Baba S, Morioka S. Treatment of intestinal Behcet's disease. In : Inaba G, ed. Behcet's Disease : Pathogenetic mechanism and clinical future. Japan Medical Research Foundation publication ; no.18, University of Tokyo Press, Tokyo, 1982 : 559-570.
 

6章 粘膜皮膚病変

P.72 掲載の参考文献
1) Bang D, Lee ES, Lee S. Behcet's disease. Asian Skin and Skin Diseases Special Book of the 22nd World Congress of Dermatology, May 24-29, 2011, Seoul. MEDrang, Inc, Seoul. 2011 : 313-25.
 
2) Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behcet's disease. Yonsei Med J 2012 ; 53 : 35-42.
PubMed
3) Lee S, Bang D, Lee ES, Sohn S. Behcet's Disease : A guide to its clinical understanding. Textbook and Atlas. Springer Verlag, Heidelberg. 2001.
 
4) Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. New Engl J Med 1999 ; 341 : 1284-91.
PubMed
5) Bang D, Honma T, Saito T, Nakagawa S, Ueki H, Lee S. The pathogenesis of vascular changes in erythema nodosum-like lesions of Behcet's syndrome : an electron microscopic study. Hum Pathol 1987 ; 18 : 1172-9.
PubMed
6) Bang D, Honma T, Saito T, Nakagawa S, Ueki H, Lee S. Ultrastructure of vascular changes in cutaneous manifestations of Behcet's disease. Acta Derm Venereol 1988 ; 68 : 33-40.
PubMed
7) Chun SI, Su WP, Lee S. Histopathologic study of cutaneous lesions in Behcet's syndrome. J Dermatol 1990 ; 17 : 333-41.
PubMed
8) Nazzaro P. Cutaneous manifestations of Behcet's disease. In : Behcet's disease. International Symposium on Behcet's disease, Rome, 1964. Monacelli M, Nazzaro P, eds. S Karger, Basel. 1966 : 15-41.
 
9) International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
 
10) International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD) : a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014 ; 28 : 338-47.
 
11) Kurokawa MS, Yoshikawa H, Suzuki N. Behcet's disease. Semin Respir Crit Care Med 2004 ; 25 : 557-68.
PubMed
12) Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet's disease. Yonsei Med J 2007 ; 48 : 573-85.
PubMed
13) Balabanova M, Calamia KT, Perniciaro C, O'Duffy JD. A study of the cutaneous manifestations of Behcet's disease in patients from the United States. J Am Acad Dermatol 1999 ; 41 : 540-5.
PubMed
14) Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, et al. Mucocutaneous criteria for the diagnosis of Behcet's disease : an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995 ; 32 : 968-76.
PubMed
15) Jorizzo JL, Taylor RS, Schmalstieg FC, Solomon AR Jr, Daniels JC, Rudloff HE, et al. Complex aphthosis : a forme fruste of Behcet's syndrome? J Am Acad Dermatol 1985 ; 13 : 80-4.
PubMed
16) Kerkeni N, Zaraa I, Ayachi J, El Euch D, Mokni M, Ben Osman A. Behcet's disease : A profile of mucocutaneous features. Acta Dermatovenerol Alp Pannonica Adriat 2010 ; 19 : 11-5.
 
17) Lee ES, Bang D, Lee S. Dermatologic manifestation of Behcet's disease. Yonsei Med J 1997 ; 38 : 380-9.
 
18) Mat C, Bang D, Melikoglu M. The mucocutaneous mainfestations and pathergy reaction in Behcet's disease. In : Yazici Y, Yazici H, editors. Behcet's syndrome. Springer Verlag, New York. 2010 : 53-72.
 
19) Mat C, Yurdakul S, Sevim A, Ozyazgan Y, Tuzun Y. Behcet's syndrome : facts and controversies. Clin Dermatol 2013 ; 31 : 352-61.
PubMed
20) Plotkin GR. Miscellaneous clinical manifestations, Part II : Gastrointestinal, hepatic, splenic, pancreatic, genitourinary, and dermatologic features. In Behcet's disease : A contemporary synopsis. Plotkin GR, Calabro JJ, O'Duffy JD, eds. Futura Publishing Co., INC, New York. 1988 : 257-68.
 
21) Vaiopoulos G, Konstantopoulou P, Evangelatos N, Kaklamanis PH. The spectrum of mucocutaneous manifestations in Adamantiades-Behcet's disease in Greece. J Eur Acad Dermatol Venereol 2010 ; 24 : 434-8.
 
22) Alpsoy E, Uzun S, Akman A, Acar MA, Memisoglu HR, Basaran E. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behcet's disease. J Eur Acad Dermatol Venereol 2003 ; 17 : 521-4.
PubMed
23) Boyvat A, Heper AO, Kocyigit P, Erekul S, Gurgey E. Can specific vessel-based papulopustular lesions of Behcet's disease be differentiated from nonspecific follicular-based lesions clinically? Int J Dermatol 2006 ; 45 : 814-8.
PubMed
24) Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis 2004 ; 63 : 1450-2.
 
25) Kalkan G, Karadag AS, Astarci HM, Akbay G, Ustun H, Eksioglu M. A histopathological approach : when papulopustular lesions should be in the diagnostic criteria of Behcet's disease? J Eur Acad Dermatol Venereol 2009 ; 23 : 1056-60.
PubMed
26) Kokturk A. Clinical and pathological manifestations with differential diagnosis in Behcet's disease. Patholog Res Int 2012 ; 2012 : 690390.
PubMed
27) Kim HJ, Bang D, Lee SH, Yang DS, Kim DH, Lee KH, et al. Behcet's syndrome in Korea : a look at the clinical picture. Yonsei Med J 1988 ; 29 : 72-8.
 
28) Gharibdoost F, Davatchi F, Shahram F, Akbarian M, Chams C, Chams H, et al. Clinical manifestations of Behcet's disease in Iran : analysis of 2176 cases. In : Behcet's Disease Proceedings of the Sixth International Conference on Behcet's Disease, Paris, 30 June to 1 July 1993. Godeau P, Wechsler B, eds. Elsevier Science Publishers, Amsterdam. 1993 : 153-8.
 
29) Sharquie KE, Al-Araji A, Hatem A. Oral pathergy test in Behcet's disease. Br J Dermatol 2002 ; 146 : 168-9.
PubMed
30) Bang D, Hur W, Lee ES, Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behcet's disease. J Dermatol 1995 ; 22 : 926-9.
PubMed
31) Lehner T. Pathology of recurrent oral ulceration and oral ulceration in Behcet's syndrome : light, electron and fluorescence microscopy. J Pathol 1969 ; 97 : 481-94.
PubMed
32) Ambrose NL, Haskard DO. Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 2013 ; 9 : 79-89.
PubMed
33) Oh SH, Han EC, Lee JH, Bang D. Comparison of the clinical features of recurrent aphthous stomatitis and Behcet's disease. Clin Exp Dermatol 2009 ; 34 : e208-12.
PubMed
34) Main DM, Chamberlain MA. Clinical differentiation of oral ulceration in Behcet's disease. Br J Rheumatol 1992 ; 31 : 767-70.
PubMed
35) Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet's disease in Iran : analysis of 6500 cases. Int J Rheum Dis 2010 ; 13 : 367-73.
PubMed
36) Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behcet's disease in 661 cases : a multicentre study. Br J Dermatol 2007 ; 157 : 901-6.
 
37) Kontogiannis V, Powell RJ. Behcet's disease. Postgrad Med J 2000 ; 76 : 629-37.
PubMed
38) Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. Am Fam Physician 2012 ; 85 : 254-62.
PubMed
39) Demirkesen C, Tuzuner N, Mat C, Senocak M, Buyukbabani N, Tuzun Y, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol 2001 ; 116 : 341-6.
PubMed
40) Lee YS, Lee SW, Lee JR, Lee SC. Erythema induratum with pulmonary tuberculosis : histopathologic features resembling true vasculitis. Int J Dermatol 2001 ; 40 : 193-6.
PubMed
41) Lee H, Kim SH, Lee SW, Zheng Z, Bang D, Kim do Y. A case of extranodal NK/T cell lymphoma mimicking refractory Behcet's disease. Acta Derm Venereol 2015 ; 95 : 491-2
 
42) Quere I, Leizorovicz A, Galanaud JP, Presles E, Barrellier MT, Becker F, et al. Superficial venous thrombosis and compression ultrasound imaging. J Vasc Surg 2012 ; 56 : 1032-8.e1.
 
43) Jung JY, Kim DY, Bang D. Leg ulcers in Behcet's disease. Br J Dermatol 2008 ; 158 : 178-9.
PubMed
44) Oh SH, Lee JH, Shin JU, Bang D. Dermatological features in Behcet disease-associated vena cava obstruction. Br J Dermatol 2008 ; 159 : 555-60.
PubMed
45) Varol A, Seifert O, Anderson CD. The skin pathergy test : innately useful? Arch Dermatol Res 2010 ; 302 : 155-68.
PubMed
46) Dilgen N, Konice M, Aral O, Ocal L, Inanc M, Gul A. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease : confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 1993 ; 52 : 823-5.
 
47) Murray PI, Aboteen N. Complication of acupuncture in a patient with Behcet's disease. Br J Ophthalmol 2002 ; 86 : 476-7.
 
48) Cho S, Kim J, Cho SB, Zheng Z, Choi MJ, Kim DY, et al. Immunopathogenic characterization of cutaneous inflammation in Behcet's disease. J Eur Acad Dermatol Venereol 2014 ; 28 : 51-7.
 

7章 眼症状

P.87 掲載の参考文献
1) al-Aboosi MM, al Salem M, Saadeh A, al-Jamal M, Hijawi M, Khammash M, et al. Behcet's disease : clinical study of Jordanian patients. Int J Dermatol 1996 ; 35 : 623-5.
PubMed
2) Hamdan A, Mansour W, Uthman I, Masri AF, Nasr F, Arayssi T. Behcet's disease in Lebanon : clinical profile, severity and two-decade comparison. Clin Rheumatol 2006 ; 25 : 364-7.
PubMed
3) Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Adawi M, et al. Behcet's disease in Israel : the influence of ethnic origin on disease expression and severity. J Rheumatol 2001 ; 28 : 1033-6.
PubMed
4) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
 
5) Mousa AR, Marafie AA, Rifai KM, Dajani AI, Mukhtar MM. Behcet's disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol 1986 ; 15 : 310-32.
 
6) Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet's disease : An analysis of 880 patients. Am J Ophthalmol 2004 ; 138 : 373-80.
PubMed
7) Kim DY, Choi MJ, Cho S, Kim DW, Bang D. Changing clinical expression of Behcet disease in Korea during three decades (1983-2012) : chronological analysis of 3674 hospital-based patients. Br J Dermatol 2014 ; 170 : 458-61.
 
8) Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T. Recent epidemiological features of Behcet's disease in Japan. In Behcet's Disease. Godeau P, Wechsler B, eds, Excerpta Medica, Amsterdam. 1993 : 145-151.
 
9) Atmaca LS. Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol 1989 ; 227 : 340-4.
PubMed
10) Atmaca LS, Batioglu F. The efficacy of cyclosporin-a in the treatment of Behcet's disease. Ophthalmic Surg 1994 ; 25 : 321-7.
PubMed
11) Ozdal PC, Ortac S, Taskintuna I, Firat E. Posterior segment involvement in ocular Behcet's disease. Eur J Ophthalmol 2002 ; 12 : 424-31.
PubMed
12) Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behcet's disease in Japan : ophthalmologic aspects. Trans Am Ophthalmol Soc 1979 ; 77 : 225-79.
 
13) Nakahara H, Kaburaki T, Takamoto M, Okinaga K, Matsuda J, Konno Y, et al. Statistical analyses of Endogenous Uveitis Patients (2007-2009) in central Tokyo area and Comparison with Previous Studies (1963-2006). Ocul Immunol Inflamm 2014 ; 25 : 1-6.
 
14) Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol 2012 ; 56 : 432-5.
PubMed
15) 稲葉裕 : ベーチェット病全国疫学調査-患者数の推計. 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 研究報告書. ベーチェット病に関する調査研究. 平成16年度総括・分担研究報告書, 89-90, 2005.
 
16) 大野重明, 蕪城俊克, 北市伸義, 他. ベーチェット病眼病変診療ガイドライン作成委員会. Behcet病 (ベーチェット病) 眼病変診療ガイドライン. 日眼会誌 2012 ; 116 : 394-426. <http://www.nichigan.or.jp/member/guideline/behcet.jsp>
 
17) Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in Behcet disease. J Glaucoma 2004 ; 13 : 441-4.
PubMed
18) Sheybani A, Harocopos GJ, Rao PK. Immunohistochemical study of epiretinal membranes in patients with uveitis. J Ophthalmic Inflamm Infect 2012 ; 2 : 243-8.
PubMed
19) Al-Dhibi H, Abouammoh M, Al-Harthi E, Al-Gaeed A, Larsson J, Abboud E, et al. Macular hole in Behcet's disease. Indian J Ophthalmol 2011 ; 59 : 359-62.
PubMed
20) Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Behcet disease. Ocul Immunol Inflamm 2009 ; 17 : 41-6.
PubMed
21) Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Br J Ophthalmol 2011 ; 95 : 1245-50.
PubMed
22) Gedik S, Akova Y, Yilmaz G, Bozbeyoglu S. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behcet's disease. Ocul Immunol Inflamm 2005 ; 13 : 51-8.
PubMed
23) Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behcet's disease. Graefes Arch Clin Exp Ophthalmol 2010 ; 248 : 709-14.
PubMed
24) Demiroglu H, Barista I, Dundar S. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 1997 ; 104 : 701-5.
PubMed
25) Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet's disease : an international collaborative study. Br J Ophthalmol 2007 ; 91 : 1579-82.
PubMed
26) Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behcet disease. Ophthalmology 1995 ; 102 : 317-21.
PubMed
27) Taylor SR, Singh J, Menezo V, Wakefield D, Mc-Cluskey P, Lightman S. Behcet disease : visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011 ; 152 : 1059-66.
PubMed
28) Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 2005 ; 243 : 1147-52.
PubMed
29) Kaburaki T, Takamoto M, Numaga J, Kawashima H, Araie M, Ohnogi Y, et al. Genetic association of HLA-A*2601 with ocular Behcet's disease in Japanese patients. Clin Exp Rheumatol 2010 ; 28 (4 Suppl 60) : S39-44.
 
30) Mamo JG. The rate of visual loss in Behcet's disease. Arch Ophthalmol 1970 ; 84 : 451-2.
PubMed
31) Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 2004 ; 111 : 810-5.
PubMed
32) Kacmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, et al. Ocular inflammation in Behcet disease : incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 2008 ; 146 : 828-36.
 
33) Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, et al. Colchicine in Behcet's disease. Lancet 1977 ; 2 (8046) : 1037.
PubMed
34) Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989 ; 1 (8647) : 1093-6.
PubMed
35) Ozyazgan Y, Yurdakul S, Yazici H, Tuzun B, Iscimen A, Tuzun Y, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome : a single masked trial. Br J Ophthalmol 1992 ; 76 : 241-3.
PubMed
36) Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008 ; 146 : 837-44.
PubMed
37) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
PubMed
38) Okada AA, Goto H, Ohno S, Mochizuki M ; Ocular Behcet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-8.
 
39) Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behcet's disease : evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999 ; 38 : 728-33.
PubMed
40) Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet's disease activity index. Rheumatology (Oxford) 2004 ; 43 : 73-8.
PubMed
41) Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, et al. Behcet's disease ocular attack score 24 : evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol 2014 : 58 ; 120-30.
PubMed
42) Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab ver sus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010 ; 94 : 284-8.
 
43) Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-84.
PubMed
44) Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008 ; 146 : 845-50.
PubMed
45) Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease : a 24-month follow-up study. Rheumatology (Oxford) 2007 ; 46 : 1161-4.
PubMed
46) Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behcet's disease : a case report and review of the literature. Clin Exp Rheumatol 2007 ; 25 (4 Suppl 45) : S99-102.
 
47) Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 2004 ; 63 : 744-5.
PubMed
48) Kasugai C, Watanabe D, Mizutani K, Masuda Y, Zako M, Mukai T, et al. Infliximab treatment of severe genital ulcers associated with Behcet disease. J Am Acad Dermatol 2010 ; 62 : 162-4.
PubMed
49) Donghi D, Mainetti C. Infliximab for the treatment of refractory Adamantiades-Behcet disease with articular, intestinal, cerebral and ocular involvement. Dermatology 2010 ; 220 : 282-6.
PubMed
50) Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009 ; 48 : 1012-3.
PubMed
51) Abalos-Medina GM, Sanchez-Cano D, Ruiz-Villaverde G, Ruiz-Villaverde R, Quirosa Flores S, Raya Alvarez E. Successful use of infliximab in a patient with neuro-Behcet's disease. Int J Rheum Dis 2009 ; 12 : 264-6.
 
52) Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al ; EULAR Expert Committee. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-62.
PubMed
53) Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990 ; 322 : 281-5.
PubMed
54) Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome : effects on long-term prognosis. Arthritis Rheum 1997 ; 40 : 769-74.
PubMed
55) Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998 ; 12 (Pt 5) : 783-8.
 
56) Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006 ; 244 : 1692-5.
PubMed
57) Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 ; 87 : 423-31.
PubMed
58) Matsuo T, Takahashi M, Inoue Y, Egi K, Kuwata Y, Yamaoka A. Ocular attacks after phacoemulsification and intraocular lens implantation in patients with Behcet disease. Ophthalmologica 2001 ; 215 : 179-82.
PubMed
59) Sakai T, Kanetaka A, Noro T, Tsuneoka H. Intraocular surgery in patients receiving infliximab therapy for Behcet disease. Jpn J Ophthalmol 2010 ; 54 : 360-1.
PubMed
60) Elgin U, Berker N, Batman A, Soykan E. Trabeculectomy with mitomycin C in secondary glaucoma associated with Behcet disease. J Glaucoma 2007 ; 16 : 68-72.
PubMed
61) Iwao K, Inatani M, Seto T, Takihara Y, Ogata-Iwao M, Okinami S, et al. Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma : a retrospective cohort study. J Glaucoma 2014 ; 23 : 88-94.
PubMed
62) Iwao K, Inatani M, Tanihara H ; Japanese Steroid-Induced Glaucoma Multicenter Study Group. Success rates of trabeculotomy for steroid-induced glaucoma : a comparative, multicenter, retrospective cohort study. Am J Ophthalmol 2011 ; 151 : 1047-56.
PubMed
63) Okada AA, Wakabayashi T, Morimura Y, Kawahara S, Kojima E, Asano Y, et al. Trans-Tenon's retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol 2003 ; 87 : 968-71.
PubMed

8章 関節病変

P.96 掲載の参考文献
1) Nanke Y, Kotake S, Ogasawara K, Shimakawa M, Takasawa S, Ujihara H, et al. Raised plasma adrenomedullin level in Behcet's disease patients. Mod Rheumatol 2003 ; 13 : 139-42.
PubMed
2) Yurdakul S, Yazici H, Tuzun Y, Pazarli H, Yalcin B, Altac M, et al. The arthritis of Behcet's disease : a prospective study. Ann Rheum Dis 1983 ; 42 : 505-15.
PubMed
3) Ben-Dov I, Zimmerman J. Deforming arthritis of the hands in Behcet's disease. J Rheumatol 1982 ; 9 : 617-8.
PubMed
4) Benamour S, Zeroual B, Alaoui FZ. Joint manifestations in Behcet's disease. A review of 340 cases. Rev Rhum Engl Ed 1998 ; 65 : 299-307.
PubMed
5) Vernon-Roberts B, Barnes CG, Revell PA. Synovial pathology in Behcet's syndrome. Ann Rheum Dis 1978 ; 37 : 139-45.
PubMed
6) Ait Badi MA, Zyani M, Kaddouri S, Niamane R, Hda A, Algayres JP. Skeletal manifestations in Behcet's disease : A report of 79 cases. Rev Med Interne 2008 ; 4 : 277-82.
PubMed
7) Frikha F, Marzouk S, Kaddour N, Frigui M, Bahloul Z. Destructive arthritis in Behcet's disease : a report of eight cases and literature review. Int J Rheum Dis 2009 ; 12 : 250-5.
PubMed
8) Yurtkuran M, Alp A, Sivrioglu K, Dilek K, Tamgac F, et al. Hand involvement in Behcet's disease. Joint Bone Spine 2006 ; 73 : 679-83.
PubMed
9) Armas JB, Davies J, Davis M, Lovell C, McHugh N. Atypical Behcet's disease with peripheral erosive arthropathy and pyoderma gangrenosum. Clin Exp Rheumatol 1992 ; 10 : 177-80.
PubMed
10) Duzgun N, Ates A. Erosive arthritis in a patient with Behcet's disease. Rheumatol Int 2003 ; 23 : 265-7.
 
11) Kotter I, Durk H, Eckstein A, Zierhut M, Fierlbeck G, Saal JG. Erosive arthritis and posterior uveitis in Behcet's disease : treatment with interferon alpha and interferon gamma. Clin Exp Rheumatol 1996 ; 14 : 313-5.
PubMed
12) Jawad AS, Goodwill CJ. Behcet's disease with erosive arthritis. Ann Rheum Dis 1986 ; 45 : 961-2.
PubMed
13) Aydin G, Keles I, Atalar E, Orkun S. Extensive erosive arthropathy in a patient with Behcet's disease : case report. Clin Rheumatol 2005 ; 24 : 645-7.
 
14) Nanke Y, Kobashigawa T, Yago T, Ichikawa N, Yamanaka H, Kotake S. Bone erosion of the sternocostal joint in a patient with Behcet's disease. Jpn J Clin Immunol 2009 ; 32 : 186-8.
 
15) Crozier F, Arlaud J, Tourniaire P, Bodiou Y, Christides C, Paris M, et al. Manubrio-sternal arthritis and Behcet's disease : report of 3 cases. J Radiol 2003 ; 84 : 1978-81.
 
16) Chang HK, Lee DH, Jung SM, Choi SJ, Kim JU, Choi YJ, et al. The comparison between Behcet's disease and spondyloarthritides : does Behcet's disease belong to the spondyloarthropathy complex? J Korean Med Sci 2002 ; 17 : 524-9.
 
17) Chamberlain MA, Robertson RJ. A controlled study of sacroiliitis in Behcet's disease. Br. J. Rheumatol 1993 ; 32 : 693-8.
PubMed
18) Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999 ; 341 : 1284-91.
PubMed
19) Gibson T, Laurent R, Highton J, Wilton M, Dyson M, Millis R. Synovial histopathology of Behcet's syndrome. Ann Rheum Dis 1981 ; 40 : 376-81.
PubMed
20) Moll C, Bogas M, Gomez-Puerta JA, Celis R, Vazquez I, Rodriguez F, et al. Macroscopic features of knee synovitis in early untreated Behcet's disease and psoriatic arthritis. Clin Rheumatol 2009 ; 28 : 1053-7.
PubMed
21) Canete JD, Celis R, Noordenbos T, Moll C, Gomez-Puerta JA, Pizcueta P, et al. Distinct synovial immunopathology in Behcet disease and psoriatic arthritis. Arthritis Res Ther 2009 ; 11 : R17.
 
22) Nanke Y, Kotake S, Momohara S, Tateishi M, Yamanaka H, Kamatani N. Synovial histology in three Behcet's disease patients with orthopedic surgery. Clin Exp Rheumatol 2002 ; 20 (4 Suppl 26) : S35-9.
 
23) Koca SS, Akbulut H, Dag S, Artas H, Isik A. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behcet's disease. Tohoku J Exp Med 2007 ; 213 : 297-304.
PubMed
24) Uyanik A, Albayrak F, Uyanik MH, Dursun H, Keles M, Cetinkaya R. Antibodies directed to cyclic citrullinated peptide in familial Mediterranean fever. Rheumatol Int 2010 ; 30 : 467-71.
PubMed
25) Cho SB, Lee JH, Ahn KJ, Bae BG, Kim T, Park YB, et al. Anti-cycle citrullinated peptide antibodies and joint involvement in Behcet's disease. Yonsei Med J 2012 ; 53 : 759-64.
 
26) Ceccarelli F, Priori R, Iagnocco A, Coari G, Accorinti M, Pivetti Pezzi P, et al. Knee joint synovitis in Behcet's disease : a sonographic study. Clin Exp Rheumatol 2007 ; 25 : S76-9.
PubMed
27) Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, et al. Arthritis of the finger joints : a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum 1999 ; 42 : 1232-45.
PubMed
28) Sahin M, Yildiz M, Tunc SE, Cerci S, Suslu H, Cure E, et al. The usefulness of Tc-99m-MDP bone scintigraphy in detection of articular involvement of Behcet's disease. Ann Nucl Med 2006 ; 20 : 649-53.
PubMed
29) Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001 ; 44 : 2686-92.
 

9章 消化管病変

P.106 掲載の参考文献
1) Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther 2003 ; 5 : 139-46.
PubMed
2) Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999 ; 341 : 1284-91.
PubMed
3) Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behcet's disease : review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981 ; 24 : 103-6.
PubMed
4) Moon CM, Cheon JH, Shin JK, Jeon SM, Bok HJ, Lee JH, et al. Prediction of free bowel perforation in patients with intestinal Behcet's disease using clinical and colonoscopic findings. Dig Dis Sci 2010 ; 55 : 2904-11.
PubMed
5) Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011 ; 90 : 125-32.
PubMed
6) Nishiyama M, Nakae K, Yukawa S, Hashimoto T, Inaba G, Mochizuki M, et al. A study of comparison between the nationwide epidemiological survey in 1991 and previous surveys on Behcet's disease in Japan. Environ Health Prev Med 1999 ; 4 : 130-4.
PubMed
7) Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease : a single center experience in Korea. J Korean Med Sci 2009 ; 24 : 52-6.
 
8) Zhang Z, He F, Shi Y. Behcet's disease seen in China : analysis of 334 cases. Rheumatol Int 2013 ; 33 : 645-8.
 
9) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-13.
PubMed
9) Zou J, Shen Y, Ji DN, Zheng SB, Guan JL. Endoscopic findings of gastrointestinal involvement in Chinese patients with Behcet's disease. World J Gastroenterol 2014 ; 20 : 17171-8.
PubMed
10) Yurdakul S, Tuzuner N, Yurdakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behcet's syndrome : a controlled study. Ann Rheum Dis 1996 ; 55 : 208-10.
PubMed
11) Ideguchi H, Suda A, Takeno M, Miyagi R, Ueda A, Ohno S,et al. Gastrointestinal manifestations of Behcet's disease in Japan : a study of 43 patients. Rheumatol Int 2014 ; 34 : 851-6.
PubMed
12) Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012 ; 380 : 1606-19.
PubMed
13) Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012 ; 380 : 1590-605.
PubMed
14) Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis : linking host genetics and the microbiome. Gut 2013 ; 62 : 1505-10.
PubMed
15) Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity 2014 ; 40 : 843-54.
 
16) Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev 2015 ; 14 : 269-76. doi. 10. 1016/j.autrev. 2014. 11. 009.
 
17) Hatemi G, Yazici H. Behcet's syndrome and micro-organisms. Best Pract Res Clin Rheumatol 2011 ; 25 : 389-406.
PubMed
18) Lee RG. The colitis of Behcet's syndrome. Am J Surg Pathol 1986 ; 10 : 888-93.
PubMed
19) Wang ZK, Shi H, Wang SD, Liu J, Zhu WM, Yang MF, et al. Confusing untypical intestinal Behcet's disease : Skip ulcers with severe lower gastrointestinal hemorrhage. World J Gastrointest Endosc 2014 ; 6 : 27-31.
PubMed
20) Baba S, Maruta M, Ando K, Teramoto T, Endo I. Intestinal Behcet's disease : report of five cases. Dis Colon Rectum 1976 ; 19 : 428-40.
 
21) Koklu S, Yuksel O, Onur I, Unverdi S, Biyikoglu I, Akbal E, et al. Ileocolonic involvement in Behcet's disease : endoscopic and histological evaluation. Digestion 2010 ; 81 : 214-7.
PubMed
22) Hamdulay SS, Cheent K, Ghosh C, Stocks J, Ghosh S, Haskard DO. Wireless capsule endoscopy in the investigation of intestinal Behcet's syndrome. Rheumatology (Oxford) 2008 ; 47 : 1231-4.
PubMed
23) Neves FS, Fylyk SN, Lage LV, Ishioka S, Goldenstein-Schainberg C, Sakai P, et al. Behcet's disease : clinical value of the video capsule endoscopy for small intestine examination. Rheumatol Int 2009 ; 29 : 601-3.
PubMed
24) Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, et al. Development and validation of novel diagnostic criteria for intestinal Behcet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol 2009 ; 104 : 2492-9.
PubMed
25) Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet's disease : indication of anti-TNF alpha monoclonal antibodies. J Gastroenterol 2014 ; 49 : 156-62.
PubMed
26) Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 605-13.
PubMed
27) Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol 2012 ; 18 : 5771-8.
PubMed
28) Kobashigawa T, Okamoto H, Kato J, Shindo H, Imamura T, Iizuka BE, et al. Ulcerative colitis followed by the development of Behcet's disease. Intern Med 2004 ; 43 : 243-7.
PubMed
30) Suzuki O, Sekishita Y, Shiono T, Fujimori M, Katoh H. Three cases of panperitonitis due to intestinal Behcet's disease with perforation, as to the usefulness of steroid medication and ileostomy. Jpn J Gastroenterol Surg 2002 ; 35 : 1817-20.
 
31) Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
32) Humes DJ, Fleming KM, Spiller RC, West J. Concurrent drug use and the risk of perforated colonic diverticular disease : a population-based case-control study. Gut 2011 ; 60 : 219-24.
PubMed
33) Gravante G, Yahia S. Medical influences, surgical outcomes : role of common medications on the risk of perforation from untreated diverticular disease. World J Gastroenterol 2013 ; 19 : 5947-52.
 
34) Curtis JR, Xie F, Chen L, Spettell C, McMahan RM, Fernandes J, et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 2011 ; 63 : 346-51.
PubMed
35) Baba S, Morioka S. Treatment of Intestinal Behcet disease. In : Inaba G, editor. Behcet's disease. University of Tokyo Press, Tokyo 1982 : 559-70.
 
36) Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C. New approaches in the treatment of Adamantiades-Behcet's disease. Curr Opin Rheumatol 2006 ; 18 : 3-9.
PubMed
37) Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-64.
PubMed
38) Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, et al. Development of consensus statements for the diagnosis and management of intestinal Behcet's disease using a modified Delphi approach. J Gastroenterol 2007 ; 42 : 737-45.
PubMed
39) ベーチェット病に関する調査研究班. 腸管ベーチェット病診療ガイドライン平成21年度案-コンセンサス・ステートメントに基づく-. 難治性疾患克服研究事業厚生労働省研究費補助金 平成20～22年度総括・分担研究報告書, 2011
 
40) Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet's disease. Cell Biochem Biophys 2014 ; 69 : 735-9.
 
41) Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, et al. Efficacy of Infliximab in patients with intestinal Behcet's disease refractory to conventional medication. Intern Med 2013 ; 52 : 1855-62.
PubMed
42) Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009 ; 48 : 1012-3.
PubMed
43) Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease : a case report. Gastroenterology 2001 ; 120 : 995-9.
PubMed
44) Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001 ; 49 : 725-8.
 
45) Ju JH, Kwok SK, Seo SH, Yoon CH, Kim HY, Park SH. Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab : rapid healing of Behcet's ulcer with infliximab. Clin Rheumatol 2007 ; 26 : 1383-5.
PubMed
46) Maruyama Y, Hisamatsu T, Matsuoka K, Naganuma M, Inoue N, Ogata H, et al. A case of intestinal Behcet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012 ; 51 : 2125-9.
PubMed
47) Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behcet's disease : maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis 2009 ; 15 : 1769-71.
PubMed
48) Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease. Mod Rheumatol 2011 ; 21 : 184-91.
PubMed
49) Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006 ; 54 : 711-5.
PubMed
50) Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P ; French Network of Pharmacovigilance Centers. Arterial and venous thromboembolic events during anti-TNF therapy : a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009 ; 19 : 355-64.
 
51) Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behcet's disease. Clin J Gastroenterol 2014 ; 7 : 205-12.
PubMed
52) Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007 ; 46 : 736-41.
PubMed
53) Bradbury AW, Milne AA, Murie JA. Surgical aspects of Behcet's disease. Br J Surg 1994 ; 81 : 1712-21.
PubMed
54) Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-602.
PubMed
55) Choi IJ, Kim JS, Cha SD, Jung HC, Park JG, Song IS, et al. Long-term clinical course and prognostic factors in intestinal Behcet's disease. Dis Colon Rectum 2000 ; 43 : 692-700.
PubMed
56) 山名征三, 青井克行 (厚生省特定疾患ベーチェット病調査研究班). ベーチェット病の術後合併症の予防-その2. 平成4年度研究業績. 1993 : 163-5.
 
57) Chung MJ, Cheon JH, Kim SU, Park JJ, Kim TI, Kim NK, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behcet disease. J Clin Gastroenterol 2010 ; 44 : e116-22.
PubMed
58) Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000 ; 95 : 2848-51.
PubMed
59) Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet's disease during the first five years. Dig Dis Sci 2013 ; 58 : 496-503.
PubMed
60) Yamada M, Shiroeda H, Nomura T, Hayashi R, Sato K, Tsutsumi M, et al. Colon cancer arising in an ulcer scar due to intestinal Behcet's disease. Intern Med 2011 ; 50 : 429-32.
 
61) Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol 2014 ; 20 : 16389-97.
PubMed

10章 神経ベーチェット病

P.123 掲載の参考文献
1) Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther 2003 ; 5 : 139-46.
PubMed
2) Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
3) Serdaroglu P. Behcet's disease and the nervous system. J Neurol 1998 ; 245 : 197-205.
PubMed
4) Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, et al. Neurological manifestations of Behcet's disease in Japan : a study of 54 patients. J Neurol 2010 ; 257 : 1012-20.
PubMed
5) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Clinical characteristics of neuro-Behcet's disease in Japan : a multicenter retrospective analysis. Mod Rheumatol 2012 ; 22 : 405-13.
PubMed
6) Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications in Behcet's syndrome. Brain 1999 ; 122 : 2183-94.
PubMed
7) Siva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol 2004 ; 17 : 347-57.
PubMed
8) Akman-Demir G, Serdaroglu P, Tasci B. The Neuro-Behcet Study Group. Clinical patterns of neurological involvement in Behcet's disease : evaluation of 200 patients. Brain 1999 ; 122 : 2171-82.
 
9) Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-7.
PubMed
10) Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behcet's disease (Neuro-Behcet's syndrome). Curr Rheumatol Rev 2007 ; 3 : 297-303.
 
11) Siva A, Hirohata S. Behcet's syndrome and the nervous system. In : Yazici Y, Yazici H, eds. Behcet's syndrome. Springer, New York. 2010 : 95-113.
 
12) Al-Araji A, Kidd DP. Neuro-Behcet's disease : epidemiology, clinical characteristics, and management. Lancet Neurol 2009 ; 8 : 192-204.
PubMed
13) Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998 ; 159 : 181-5.
PubMed
14) Saadoun D, Wechsler B, Resche-Rigon M, Trad S, Le Thi Huong D, Sbai A, et al. Cerebral venous thrombosis in Behcet's disease. Arthritis Rheum (Arthritis Care Res) 2009 ; 61 : 518-26.
 
15) Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Bletry O, et al. Cerebral venous sinus thrombosis in Behcet's disease : clinical study and long-term follow-up of 25 cases. Neurology 1992 ; 42 : 614-8.
PubMed
16) Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behcet's disease : diagnostic and prognostic aspects of neurological involvement. J Neurol 2001 ; 248 : 95-103.
PubMed
17) Tunc R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome. Ann Rheum Dis 2004 ; 63 : 1693-4.
PubMed
18) Houman MH, Hamzaoui-B'Chir S, Ben Ghorbel I, Lamloum M, Ben Ahmed M, Abdelhak S, et al. Neurologic manifestations of Behcet's disease : analysis of a series of 27 patients. Rev Med Interne 2002 ; 23 : 592-606.
PubMed
19) Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 (4 Suppl 67) : S47-53.
 
20) Saip S, Siva A, Altintas A, Kiyat A, Seyahi E, Hamuryudan V, et al. Headache in Behcet's syndrome. Headache 2005 ; 45 : 911-9.
PubMed
21) Lo Monaco A, La Corte R, Caniatti L, Borrelli M, Trotta F. Neurological involvement in North Italian patients with Behcet disease. Rheumatol Int 2006 ; 26 : 1113-9.
PubMed
22) Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999 ; 106 : 586-9.
PubMed
23) Kikuchi H, Takayama M, Hirohata S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behcet's disease. J Neurol Sci 2014 ; 337 : 80-5.
PubMed
24) Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet's disease. Mod Rheumatol 2007 ; 17 : 81-2.
PubMed
25) Matsui T, Ishida T, Tono T, Yoshida T, Sato S, Hirohata S. An attack of acute neuro-Behcet's disease during the course of chronic progressive neuro-Behcet's disease : report of two cases. Mod Rheumatol 2010 ; 20 : 621-6.
PubMed
26) Hirohata S. Histopathology of central nervous system lesions in Behcet's disease. J Neurol Sci 2008 ; 267 : 41-7.
PubMed
27) Hirohata S, Kikuchi H. Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behcet's disease. Intern Med 2012 ; 51 : 3359-65.
PubMed
28) Kocer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, et al. CNS involvement in neuro-Behcet syndrome : an MR study. AJNR Am J Neuroradiol 1999 ; 20 : 1015-24.
 
29) Hirohata S, Takeuchi A, Miyamoto T. Elevated levels of interleukin 6 in cerebrospinal fluid from patients with Neuro-Behcet's syndrome. In : Behcet's disease. O'Duffy JD, Kokmen E, eds. Marcel Dekker, New York. 1991 : 369-76.
 
30) Fujikawa K, Aratake K, Kawakami A, Aramaki T, Iwanaga N, Izumi Y, et al. Successful treatment of refractory neuro-Behcet's disease with infliximab : a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 2007 ; 66 : 136-7.
PubMed
31) Akman-Demir G, Tuzun E, Icoz S, Yesilot N, Yentur SP, Kurtuncu M, et al. Interleukin-6 in neuro-Behcet's disease : association with disease subsets and long-term outcome. Cytokine 2008 ; 44 : 373-6.
PubMed
32) Borhani Haghighi A, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, et al. CSF levels of cytokines in neuro-Behcet's disease. Clin Neurol Neurosurg 2009 ; 111 : 507-10.
PubMed
33) Siva A, Fresko II. Behcet's Disease. Curr Treat Options Neurol 2000 ; 2 : 435-48.
 
34) Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001 ; 21 : 109-11.
PubMed
35) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
PubMed
36) Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease : an open-label trial. Arthritis Rheum 2005 ; 52 : 2478-84.
PubMed
37) Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003 ; 62 : 280-1.
 
38) Hirohata S, Kamoshita H, Taketani T. Spontaneous remission of meningoencephalitis in Behcet's disease. J Rheumatol 1989 ; 16 : 1283-4.
PubMed
39) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-5.
PubMed
40) Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro- Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-8.
PubMed
41) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease. J Neurol Sci 2015 ; 349 : 143-8.
PubMed
42) Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Behcet's disease with infliximab. J Rheumatol 2005 ; 32 : 181-3.
PubMed
43) Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, et al. Infliximab for the treatment of neuro-Behcet's disease : a case series and review of the literature. Arthritis Rheum (Arthritis Care Res) 2008 ; 59 : 285-90.
 
44) Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive Neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
45) Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells : comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008 ; 58 : 1248-57.
PubMed
46) Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet's disease : a double blind, placebo controlled study. J Rheumatol 2005 ; 32 : 98-105.
PubMed
47) Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab : a case report. Clin Exp Rheumatol 2012 ; 30 (3 Suppl 72) : S73-5.
 

11章 血管病変

P.137 掲載の参考文献
1) Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther 2003 ; 5 : 139-46.
PubMed
2) Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Characteristics of vascular involvement in Behcet's disease in Japan : a retrospective cohort study. Clin Exp Rheumatol 2011 ; 29 : S47-53.
PubMed
3) Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013 ; 65 : 1-11.
 
4) Lie JT. Vascular involvement in Behcet's disease : arterial and venous and vessels of all sizes. J Rheumatol 1992 ; 19 : 341-3.
 
5) Duzgun N, Ates A, Aydintug OT, Demir O, Olmez U. Characteristics of vascular involvement in Behcet's disease. Scand J Rheumatol 2006 ; 35 : 65-8.
PubMed
6) Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloun M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behcet's disease. Clin Exp Rhewmatol 2001 ; 19 (5 Suppl 24) : S48-50.
 
7) Atzeni F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C. Behcet's disease and cardiovascular involvement. Lupus 2005 ; 14 : 723-6.
PubMed
8) Arishiro K, Nariyama J, Hoshiga M, Nakagawa A, Okabe T, Nakakoji T, et al. Vascular Behcet's Disease with coronary artery aneurysm. Intern Med 2006 ; 45 : 903-7.
PubMed
9) Geri G, Wechsler B, Thi Huong du L, Isnard R, Piette JC, Amoura Z, et al. Spectrum of cardiac lesions in Behcet disease : a series of 52 patients and review of the literature. Medicine (Baltimore) 2012 ; 91 : 25-34.
PubMed
10) Huong DL, Wechsler B, Papo T, de Zuttere D, Bletry O, Hernigou A, et al. Endomyocardial fibrosis in Behcet's disease. Ann Rheum Dis 1997 ; 56 : 205-8.
PubMed
11) Hosaka A, Miyata T, Shigematsu H, Shigematsu K, Okamoto H, Ishii S, et al. Long-term outcome after surgical treatment of arterial lesions in Behcet disease. J Vasc Surg 2005 ; 42 : 116-21.
PubMed
12) Hamza M. Large artery involvement in Behcet's disease. J Rheumatol 1987 ; 14 : 554-9.
PubMed
13) Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behcet's disease. J Rheumatol 1992 ; 19 : 402-10.
 
14) Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A. Vascular involvement in Behcet's disease : 8-year audit. World J Surg 1994 ; 18 : 948-53.
PubMed
15) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
 
16) Hamuryudan V, Yurdakul S, Moral F, Numan F, Tuzun H, Tuzuner N, et al. Pulmonary arterial aneurysms in Behcet's syndrome : a report of 24 cases. Br J Rheumatol 1994 ; 33 : 48-51.
PubMed
17) Ko GY, Byun JY, Choi BG, Cho SH. The vascular manifestations of Behcet's disease : angiographic and CT findings. Br J Radiol 2000 ; 73 : 1270-4.
PubMed
18) Kabbaj N, Benjelloun G, Gueddari FZ, Dafiri R, Imani F. Vascular involvements in Behcet disease. Based on 40 patient records. J Radiol 1993 ; 74 : 649-56.
PubMed
19) Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, et al. Vascular involvement in Behcet's disease : relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002 ; 112 : 37-43.
PubMed
20) Aydintug AO, Tokgoz G, D'Cruz DP, Gurler A, Cervera R, Duzgun N, et al. Antibodies to endothelial cells in patients with Behcet's disease. Clin Immunol Immunopathol 1993 ; 67 : 157-62.
PubMed
21) Lee KH, Chung HS, Bang D, Lee S. Behcet's dis ease sera containing antiendothelial cell antibodies promote adhesion of T lymphocytes to cultured human dermal microvascular endothelial cells. Yonsei Med J 1999 ; 40 : 152-8.
 
22) Triolo G, Accardo-Palumbo A, Triolo G, Carbone MC, Ferrante A, Giardina E. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behcet's disease : moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999 ; 91 : 330-7.
PubMed
23) Bassyouni IH, El-Wakd MM, Bassyouni RH. Soluble levels of osteopontin in patients with Behcet's disease : association with disease activity and vascular involvement. J Clin Immunol 2013 ; 33 : 361-7.
PubMed
24) Mege JL, Dilsen N, Sanguedolce V, Gul A, Bongrand P, Roux H, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993 ; 20 : 1544-9.
PubMed
25) Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease : high levels may indicate vascular involvement. Int J Dermatol 2009 ; 48 : 259-64.
PubMed
26) Kobayashi M, Ito M, Nakagawa A, Matsushita M, Nishikimi N, Sakurai T, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behcet disease. Histopathology 2000 ; 36 : 362-71.
PubMed
27) Hamuryudan V, Oz B, Tuzun H, Yazici H. The menacing pulmonary artery aneurysms of Behcet's syndrome. Clin Exp Rheumatol 2004 ; 22 : S1-3.
PubMed
28) Hirohata S, Kikuchi H. Histopathology of the ruptured pulmonary artery aneurysm in a patient with Behcet's disease. Clin Exp Rheumatol 2009 ; 27 : S91-5.
 
29) Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behcet disease (Behcet syndrome). Semin Arthritis Rheum 1979 ; 8 : 223-60.
PubMed
30) Solmaz D, Sari I, Ozpelit E, Yilmaz E. Intracardiac Thrombosis and Superior Vena Cava Syndrome in Behcet's Disease. Intern Med 2011 ; 50 : 1787-8.
PubMed
31) Kajiya T, Anan R, Kameko M, Mizukami N, Minagoe S, Hamasaki S, et al. Intracardiac thrombus, superior vena cava syndrome, and pulmonary embolism in a patient with Behcet's disease : a case report and literature review. Heart Vessels 2007 ; 22 : 278-83.
 
32) Bittencourt Mde J, Dias CM, Lage TL, Barros RS, Paz OA, Vieira Wde B. Behcet disease in association with Budd-Chiari syndrome and multiple thrombosis : case report. An Bras Dermatol 2013 ; 88 : 448-51.
PubMed
33) Sarica-Kucukoglu R, Akdag-Kose A, Kayabali M, Yazganoglu K, Disci R, Erzengin D, et al. Vascular involvement in Behcet's disease : a retrospective analysis of 2319 cases. Int J Dermatol 2006 ; 45 : 919-21.
PubMed
34) 小池茂文, 松本興治, 小久保光治, 森義雄, 村川真司, 広瀬光男. Bechet病に合併した腹部大動脈瘤術後に発生した大動脈十二指腸瘻の1例と本邦報告95例のBechet 病動脈瘤について. 日本外科学会雑誌 1988 ; 89 : 945-51.
 
35) Jayachandran NV, Rajasekhar L, Chandrasekhara PK, Kanchinadham S, Narsimulu G. Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome : a case report. Clin Rheumatol 2008 ; 27 : 265-7.
PubMed
36) Vasseur MA, Haulon S, Beregi JP, Le Tourneau T, Prat A, Warembourgh H. Endovascular treatment of abdominal aneurysmal aortitis in Behcet's disease. J Vasc Surg 1998 ; 27 : 974-6.
PubMed
37) Sahebari M, Abdollahi N, Rad MP, Abbasi B. Multiple artery aneurysms as the first presentation of Behcet disease. J Clin Rheumatol 2013 ; 19 : 161-2.
 
38) Zhao H, He B, Shen X, Qiao Z, Xu T, Lian F, et al. Aortic root dissection with left valsalva sinus perforation detected by transesophageal 3D echocardiography in a patient with Behcet's disease. J Clin Ultrasound 2014 ; 42 : 59-62.
 
39) Wakabayashi Y, Tawarahara K, Kurata C. Aneurysms of all sinuses of Valsalva and aortic valve prolapse secondary to Behcet's disease. Eur Heart J 1996 ; 17 : 1766.
PubMed
40) Kusuyama T, Nakamura Y, Yamagishi H, Shimada K, Watanabe H, Muro T, et al. Unruptured aneurysm of the sinus of valsalva with Behcet's disease. Circ J 2002 ; 66 : 107-8.
PubMed
41) Chikamori T, Doi YL, Yonezawa Y, Takata J, Kawamura M, Ozawa T. Aortic regurgitation secondary to Behcet's disease. A case report and review of the literature. Eur Heart J 1990 ; 11 : 572-6.
PubMed
42) Yakut ZI, Odev K. Pulmonary and cardiac involvement in Behcet disease : 3 case reports. Clin Appl Thromb Hemost 2007 ; 13 : 318-22.
PubMed
43) Endo LM, Rowe SM, Romp RL, Buckmaster MA, Atkinson TP. Pulmonary aneurysms and intracardiac thrombi due to Behcet's disease in an African-American adolescent with oculocutaneous albinism. Clin Rheumatol 2007 ; 26 : 1537-9.
 
44) Huong DL, Dolmazon C, De Zuttere D, Wechsler B, Godeau P, Piette JC. Complete recovery of right intraventricular thrombus and pulmonary arteritis in Behcet's disease. Br J Rheumatol 1997 ; 36 : 130-2.
PubMed
45) International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990 ; 335 : 1078-80.
 
46) Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011 ; 90 : 125-32.
PubMed
47) Mader R, Ziv M, Adawi M, Mader R, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999 ; 26 : 2404-8.
PubMed
48) Lenk N, Ozet G, Alli N, Coban O, Erbasi S. Protein C and protein S activities in Behcet's disease as risk factors of thrombosis. Int J Dermatol 1998 ; 37 : 124-5.
PubMed
49) Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behcet's disease. J Int Med Res 1998 ; 26 : 206-8.
PubMed
50) Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, et al. Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol 2005 ; 23 : S53-8.
 
51) Bassyouni IH, Gamal S, Talaat RM, Siam I. Autoantibodies against complement C1q in patients with Behcet's disease : association with vascular involvement. Mod Rheumatol 2014 ; 24 : 316-20.
PubMed
52) Karmochkine M, Boffa MC, Wechsler B, Piette JC, Godeau P. Absence of antiphospholipid antibodies in Behcet's disease. Ann Rheum Dis 1993 ; 52 : 623.
PubMed
53) Efthimiou J, Harris EN, Hughes GR. Negative anticardiolipin antibodies and vascular complications in Behcet's syndrome. Ann Rheum Dis 1985 ; 44 : 725-6.
PubMed
54) Kang HJ, Lee YW, Han SH, Cho HC, Lee KM. Anticardiolipin and anti-beta2-glycoprotein I antibodies in Behcet's disease. J Korean Med Sci 1998 ; 13 : 400-4.
PubMed
55) Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, et al. Anticardiolipin antibodies : occurrence in Behcet's syndrome. Ann Rheum Dis 1984 ; 43 : 746-8.
PubMed
56) Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behcet's disease : a reassessment. Rheumatology (Oxford) 2001 ; 40 : 192-5.
PubMed
57) Nakano H, Oka H, Matsuda T, Ooka S, Imamura Y, Suzuki T, et al. Behcet's disease with vascular involvement : the contribution of anticardiolipin antibodies and thrombomodulin. Adv Exp Med Biol 2003 ; 528 : 395-8.
PubMed
58) Temizoz O, Genchellac H, Yekeler E, Demir MK, Unlu E, Ozdemir H. CT-angiographic demonstration of hepatic collateral pathways due to superior vena cava obstruction in Behcet disease. Diagnostic and interventional radiology (Ankara, Turkey) 2010 ; 16 : 302-5.
 
59) Denecke T, Staeck O, Amthauer H, Hanninen EL. PET/CT visualises inflammatory activity of pulmonary artery aneurysms in Behcet disease. Eur J Nucl Med Mol Imaging 2007 ; 34 : 970.
PubMed
60) Cho SB, Yun M, Lee JH, Kim J, Shim WH, Bang D. Detection of cardiovascular system involvement in Behcet's disease using fluorodeoxyglucose positron emission tomography. Semin Arthritis Rheum 2011 ; 40 : 461-6.
 
61) Tezuka D, Haraguchi G, Ishihara T, Ohigashi H, Inagaki H, Suzuki J, et al. Role of FDG PET-CT in Takayasu arteritis : sensitive detection of recurrences. JACC Cardiovasc Imaging 2012 ; 5 : 422-9.
PubMed
62) Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995 ; 96 : 994-1002.
PubMed
63) Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012 ; 64 : 2753-60.
PubMed
64) Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-62.
PubMed
65) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004 ; 31 : 1362-8.
PubMed
66) Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 2008 ; 14 : 1259-64.
PubMed
67) Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
68) Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P. Arterial and venous thromboembolic events during anti-TNF therapy : a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 2009 ; 19 : 355-64.
 
69) Baki K, Villiger PM, Jenni D, Meyer T, Beer JH. Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms : complete remission after infliximab treatment. Ann Rheum Dis 2006 ; 65 : 1531-2.
PubMed
70) Lee SW, Lee SY, Kim KN, Jung JK, Chung WT. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease : a case report. Clin Rheumatol 2010 ; 29 : 91-3.
PubMed
71) Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet's disease : an update. Curr Opin Rheumatol 2011 ; 23 : 24-31.
PubMed
72) Yamana S, Murashita J, Ishibe Y, Aoi K. A case of vasculo-Behcet's disease with pseudoaneurism replaced with artificial vessel using prednisolone. Studies on Behcet's disease (Behcet's disease Research Committee of Japan, Ministry of Welfare, Japan 1991), 1992 : 158-60.
 
73) Yamana S, Aoki K, Yamanishi Y, Yamaguchi M. Rupture of postoperative pseudoaneurism and successful reoperation with artificial vessel under the administration of prednisolone. Studies on Behcet's disease (Behcet's disease Research Committee of Japan, Ministry of Welfare, Japan 1995), 1996 : 104-5.
 
74) Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behcet's disease. Arthritis Rheum 2010 ; 62 : 2806-12.
PubMed
75) Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, et al. Pulmonary artery involvement and associated lung disease in Behcet disease : a series of 47 patients. Medicine (Baltimore) 2012 ; 91 : 35-48.
PubMed
76) Yasuo M, Nagano S, Yazaki Y, Koizumi T, Kitabayashi H, Imamura H, et al. Pulmonary embolism due to right ventricular thrombus in a case of Behcet's disease. Jpn Circ J 1999 ; 63 : 909-11.
 
77) Dogan SM, Birdane A, Korkmaz C, Ata N, Timuralp B. Right ventricular thrombus with Behcet's syndrome : successful treatment with warfarin and immunosuppressive agents. Tex Heart Inst J 2007 ; 34 : 360-2.
PubMed
78) Korkmaz C. Is anticoagulation unnecessary in Behcet's disease with deep venous thrombosis? Clin Rheumatol 2008 ; 27 : 405-6.
PubMed

12章 予後と治療

P.149 掲載の参考文献
1) Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, et al. Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset : long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010 ; 49 : 173-7.
 
2) Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med 1999 ; 341 : 1284-91.
PubMed
3) Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics : systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 2012 ; 51 : 887-900.
PubMed
4) Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behcet's disease. Arthritis Rheum 2010 ; 62 : 2806-12.
PubMed
5) Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behcet syndrome : a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 ; 82 : 60-76.
 
6) Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease : evolution of clinical manifestations. Medicine (Baltimore) 2011 ; 90 : 125-32.
PubMed
7) Coskun B, Ozturk P, Saral Y. Are erythema nodosum-like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behcet's disease? Int J Clin Pract 2005 ; 59 : 69-71.
PubMed
8) Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis 2004 ; 63 : 1450-2.
 
9) Taylor SR, Singh J, Menezo V, Wakefield D, Mc Cluskey P, Lightman S. Behcet disease : visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 2011 ; 152 : 1059-66.
PubMed
10) Okada AA, Goto H, Ohno S, Mochizuki M ; Ocular Behcet's Disease Research Group of Japan Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol 2012 ; 130 : 592-8.
 
11) Levy-Clarke G, Jabs DA, Read RW, Rosenbaum J T, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014 ; 121 : 785-96 e3.
 
12) Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies : systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 ; 295 : 2275-85.
PubMed
13) Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, et al. The prevalence and clinical characteristics of esophageal involvement in patients with Behcet's disease : a single center experience in Korea. J Korean Med Sci 2009 ; 24 : 52-6.
 
14) Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 2012 ; 46 : e38-45.
PubMed
15) Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis 2011 ; 17 : 1594-602.
PubMed
16) Naganuma M, Iwao Y, Inoue N, Hisamatsu T, Imaeda H, Ishii H, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behcet's disease. Am J Gastroenterol 2000 ; 95 : 2848-51.
PubMed
17) Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-α antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009 ; 48 : 1012-3.
 
18) Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004 ; 117 : 867-70.
PubMed
19) Mehta P, Laffan M, Haskard DO. Thrombosis and Behcet's syndrome in non-endemic regions. Rheumatology 2010 ; 49 : 2003-4.
PubMed
20) Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008 ; 67 : 1656-62.
PubMed
21) Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Analysis of various factors on the relapse of acute neurological attacks in Behcet's disease. Mod Rheumatol 2014 ; 24 : 961-5.
PubMed
22) Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behcet's syndrome. Clin Immunol Immunopathol 1997 ; 82 : 12-7.
PubMed
23) Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet's disease. Mod Rheumatol 2007 ; 17 : 81-2.
PubMed
24) Ait Ben Haddou EH, Imounan F, Regragui W, Mouti O, Benchakroune N, Abouqal R, et al. Neurological manifestations of Behcet's disease : evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012 ; 168 : 344-9.
PubMed
25) Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behcet's disease. A follow-up study for 4 years. Adv Exp Med Biol 2003 ; 528 : 575-8.
PubMed
26) Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 2008 ; 272 : 99-105.
PubMed
27) 稲葉裕, 黒沢美智子, 藤野雄次郎, 大野重昭, 坂根剛, 中江公裕 : ベーチェット病の予後調査 (中間報告). 厚生省特定疾患調査研究事業特定疾患に関する疫学研究班平成10年度研究業績. 1998 : 165-8.
 
28) Hirohata S. Is the long-term use of systemic corticosteroids beneficial in the management of Behcet's syndrome? Nat Clin Pract Rheumatol 2006 ; 2 : 358-9.
 
29) Matsumura N, Mizushima Y. Leucocyte movement and colchicine treatment in Behcet's disease. Lancet 1975 ; 2 : 813.
PubMed
30) Hamuryudan V, Hatemi G, Tascilar K, Yurdakul S, Mat C, Ozyazgan Y, et al. Colchicine in Behcet syndrome : a longterm survey of patients in a controlled trial. J Rheumatol 2014 ; 41 : 735-8.
 
31) Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989 ; 1 : 1093-6.
PubMed
32) Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001 ; 29 : 335-6.
 
33) Kotter I, Gunaydin I, Batra M, Vonthein R, Stubiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behcet's disease under cyclosporin A (CSA) than under other medications : results of a retrospective analysis of 117 cases. Clin Rheumatol 2006 ; 25 : 482-6.
PubMed
34) Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 1999 ; 106 : 586-9.
PubMed
35) Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998 ; 12 (Pt 5) : 783-8.
 
36) Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome : effects on long-term prognosis. Arthritis Rheum 1997 ; 40 : 769-74.
PubMed
37) Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990 ; 322 : 281-5.
PubMed
38) Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi Huong D, Resche-Rigon M, et al. Azathioprine in severe uveitis of Behcet's disease. Arthritis Care Res (Hoboken) 2010 ; 62 : 1733-8.
PubMed
39) Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al. Interferon alfa-2a in the treatment of Behcet disease : a randomized placebo-controlled and double-blind study. Arch Dermatol 2002 ; 138 : 467-71.
PubMed
40) Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease : review of the literature. Semin Arthritis Rheum 2004 ; 33 : 320-35.
PubMed
41) Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 ; 128 : 443-50.
PubMed
42) Marshall SE. Behcet's disease. Best Pract Res Clin Rheumatol 2004 ; 18 : 291-311.
PubMed
43) Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behcet's syndrome : A phase 2, placebo-controlled study. N Engl J Med 2015 ; 372 : 1510-8.
PubMed
44) Desbois AC, Wechsler B, Resche-Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012 ; 64 : 2753-60.
PubMed
45) Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012 ; 22 : 298-302.
PubMed

書評

最近チェックした商品履歴

Loading...